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Chapter I 
GENERAL INTRODUCTION 
Chapter I 
Classification of rheumatoid arthritis (RA) 
Rheumatoid arthritis (RA) is a systemic condition, with chronic symmetric 
poly-arthritis as its most important manifestation. This causes, even early after disease 
onset, functional disability and irreversible radiographical damage of the joints.1,24 Next 
to the joint-involvement also extra-articular features are present e.g. nodules, 
pulmonary fibrosis, digital vasculitis, skin ulceration, lymphadenopathy, splenomegaly 
etc.4 The aetiology of RA is unknown. It has been identified in all parts of the world, 
and was found in every ethnic or racial group that has been studied. There is no one 
pathognomonic manifestation or simple diagnostic test of RA, besides this the signs 
and symptoms of RA may be transitory or fluctuating. Therefore the diagnosis of RA 
is based on criteria. The revised criteria of 1987 by the American Rheumatism 
Association (ARA) include the following clinical assessments: 1. morning stiffness of 
at least one hour; 2. arthritis in at least three joint areas with swelling or fluid; 
3. arthritis of hand joints (at least one area swollen in a wrist, MCP, or PIP joint); 
4. symmetric joint swelling and involvement; 5. subcutaneous nodules; 6. radiographic 
changes typical of RA; 7. positive rheumatoid factor. A patient can be classified as 
having RA if at least 4 of these criteria are satisfied (criteria 1-4 must have been 
present for at least 6 weeks).5,6 
Treatment of RA 
Farmaco-therapy is an important aspect of the treatment of RA. This was 
traditionally divided into three categories. All three classes improve the symptoms and 
clinical features of inflammatory synovitis. The terminology over the years has varied 
but their classification into Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (e.g. 
indomethacin, naproxen, diclofenac), corticosteroids (often used as adjuvans), and Slow 
Acting Anti-Rheumatic Drugs (SAARDs) (e.g. sulphasalazine, methotrexate, 
hydroxychloroquine, gold) is widely accepted. These SAARDs are also called Disease 
Modifying Anti-Rheumatic Drugs (DMARDs), which suggest that these agents 
influence the course of the disease. However, this influence, which is not always 
sharply defined, has not been investigated for all SAARDs and is therefore doubted 
by some. Due to this a new classification was proposed only recently. In essence, two 
categories were discerned: 1. Since all drugs are symptomatically effective, it was 
recommended that this be one determinant of the classification: the Symptom-
Modifying Anti-rheumatic Drugs (SM-ARDs) which include NSAIDs, corticosteroids, 
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and all currently known SAARDs; 2. If any of these agents subsequently show to 
modify the disease as demonstrated by prevention or decreased rate of progression of 
joint erosions and/or sustained improvement in function associated with decreased 
inflammatory synovitis, it was proposed that they be reclassified as Disease Controlling 
Anti-Rheumatic Treatment (DC-ART). SM-ARDs will be relatively easy, whereas the 
classification of DC-ARTs will be complex.7,8,9 Over the years, the drug-treatment of 
RA has considerably changed. This is mainly due to the fact that the number of 
SAARDs that became available in the treatment of RA increased during the years. The 
drug-treatment has also changed substantially for patients with recent onset of RA over 
the years. Before 1980, these patients were treated mainly with NSAIDs. This was due 
to the restricted number of SAARDs and their side-effects, which were thought to be 
more severe than the course of RA itself. After 1980 treatment with SAARDs 
(eventually in combination with NSAIDs) was initiated as early as possible to try to 
change the course of the disease. Nowadays even combinations of SAARDs are 
administered in these patients.10,11 In the study of Wijnands et al. the efficacy and 
major side-effects are described of the different SAARDs as well as of the NSAIDs 
in daily clinical practice.12,13 
Clinical assessment of RA 
The clinical assessment of RA purposes to monitor different aspects of the 
disease, e.g. the influence of treatment (side-effects, efficacy), and the course of the 
disease. Although these aspects are not independent from each other, the latter will be 
the topic of this study. In clinical trials as well as in daily clinical practice the course 
of RA can be measured by many variables. In clinical studies in which an evaluation 
takes place by one or more of these variables, these variables are also called endpoints 
(or outcomes of a study). All variables can be classified in different ways. One of the 
possible divisions is for example into laboratory-, radiographic-, clinical-, functional-, 
and health status-variables. Examples of laboratory-variables are: erythrocyte 
sedimentation rate, haemoglobin, thrombocytes; of radiographie-variables: the number 
of erosions, joint space narrowing; of clinical-variables: joint counts, visual analogue 
scales for pain or general health; of functional-variables: Health Assessment 
Questionnaires, Steinbrocker ARA classification, grip strength; of health status-
variables: Arthritis Impact Measurement Scales, Sickness Impact Profiles. 
Next to this division, the variables can be categorized into process and 
outcome measures. According to Kirwan et al.,14 process variables are assumed to be 
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the abnormal physiological occurrences that follow from its cause. Outcome is the 
suffering or loss of health experienced by an individual as a result of the process of 
the disease. Thus while process variables reflect the situation at a particular point in 
time, outcome will be integrated over the lifetime of the disease. In general process 
variables measure the "disease activity", this is represented by almost all clinical 
variables, e.g. the different joint counts measuring tenderness and/or swelling, the 
visual analogue scale measuring pain. Outcome variables can be divided into disease 
specific- and general variables. A disease specific variable is the radiographic damage 
which is a pure outcome measurement. By general outcome variables the outcome of 
different diseases can be compared. Fries et al. conceptualized outcome measurement 
(general) into five dimensions: death, disability, discomfort, iatrogenic effects, and 
economic costs.15,16 Many variables, however, measure a mixture of process and 
outcome. Grip strength and functional capacity for instance will be influenced by 
momentary disease activity as well as by irreversible joint destruction as a result of 
past disease activity. 
Until recently many variables were evaluated in clinical trials as well as in 
daily clinical practice to test the efficacy of a treatment, or to study the course of the 
disease. Due to this large number of variables the following problems occur: 
1. because all studies use many different variables it is impossible to compare the 
results of these studies with each other; 2. since statistical significance often arises by 
chance when multiple statistical tests are performed, the use of many variables makes 
it likely that any therapy will be statistically significantly efficacious on some measures 
if no correction is applied (Bonferroni); 3. investigators can decide which outcome to 
report in publications, they may report only those variables that show impressive 
results. Besides the large number of variables, little is known about the validity of 
these variables to measure disease activity. Due to this, clinical trials continue to 
include variables that are insensitive to change, even in the presence of a demonstrated 
treatment effect. To overcome this problem, a lot of studies were performed to select 
the most powerful variables (process) with respect to e.g. sensitivity to changes, the 
prognostic value for outcome.17,18,19,20'21,22,23,24,25·26 A concept how to investigate the 
validity of variables to measure disease activity was described by Tugwell, and 
Bombardier et al.27,28 The results of all these studies led to Core sets of variables, 
which include a minimal set of variables by which the clinical course should be 
evaluated. Core sets are proposed by the EULAR committee (1993),29 as well as by 
the ACR (1994)30,31 and WHO/ILAR.9 Generally, the following variables are included 
in the Core sets: a tender joint count, a swollen joint count, patient's assessment of 
12 
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pain, patient's and physician's global assessment of disease activity, patient's 
assessment of physical function, and a laboratory measurement of one acute-phase 
reactant. A radiographic score or other imaging techniques were advised. 
The development of the Core sets was an important step for future research, 
however, still some problems remain. In this thesis the following problems are 
investigated: 
Which joint count to use? 
Joint involvement, the symmetric poly-arthritis which is prerequisite for RA, 
can be measured by joint counts (JCs). A variety of JCs is used in clinical trials and 
in daily clinical practice. They differ with respect to abnormalities measured 
(tenderness, swelling, warmth, limitation of motion, and deformity of the joints) as 
well as to the number of joints included. Due to the fact that no uniformity exists in 
the use of JCs, the problems, mentioned before, arise. The Core sets of variables 
include two JCs which measure tender joints and swollen joints. Even with this 
limitation the number of JCs remains large. In Chapter 1, an evaluation of different 
JCs measuring tenderness and swelling with respect to validity, and reliability to 
measure disease activity is reported. 
In recent years the number of variables which are measured by self-
administered forms filled in by patients has increased in the assessment of RA (e.g. 
the Health Assessment Questionnaire, the visual analogue scales etc.). In Chapter 2 an 
evaluation took place of the validity and reproducibility of self-administered JCs. 
Indices of disease activity 
Even with the Core sets of variables problems as multiplicity and conflicting 
results are still appreciable. A solution would be the development of disease 
activity indices, in which several variables are combined. Many indices have been 
developed 32·33·34·35·36·37·38
 m the past either based on statistical analysis or on heuristic 
bases. Several indices are computed by variables which are not included in the Core 
sets. Due to the changed concept of measurement of disease activity by Core set 
variables, these indices cannot be used in the future. Recently, the Disease Activity 
Score (DAS), which can be calculated by Core set variables, was developed in patients 
with recent onset RA. This index / score includes among other variables a JC 
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measuring tenderness in 53 joints (the Ritchie Articular Index) and a JC measuring 
swelling in 44 joints. In Chapter 3, this DAS is modified based on the results of 
Chapters 1 and 2. Next to this, this index is investigated in patients with an extended 
disease duration versus the original study. 
Response criteria 
In clinical trials and in daily clinical practice the efficacy of treatment, or the 
clinical course of RA can be measured by Disease Activity Scores. However, an 
interpretation of these Disease Activity Scores-values into outcome measures has not 
yet been investigated. One of the disease specific outcome measures is the response 
to drug therapy, which is a combination of change in disease activity over a time-
period in combination with the level of disease activity. This response can be divided 
into the response of individual patients as well as the number of responders in groups. 
This has been investigated in Chapter 4. 
Remission 
Another outcome variable is remission. Remission is a synonym of low disease 
activity, and is the ultimate goal of treatment. In Chapter 5 remission-criteria of the 
ACR, developed in 1981, are evaluated. These criteria cannot be computed solely by 
Core set variables. Therefore a comparison is made between these criteria 
(dichotomous) and Disease Activity Score (continuous). 
Mortality 
One of the general outcome measures is the mortality of patients with RA. 
Several studies have been performed to investigate mortality and its prognostic factors. 
These studies, however, seldomly included non-selected patient groups from the start 
of the disease. Chapter 6 describes the outcome mortality of patients with recent onset 
RA. Next to this, the prognostic value of the Disease Activity Score and other 
variables was investigated. 
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VALIDITY AND RELIABILITY 
OF JOINT COUNTS 
A LONGITUDINAL STUDY IN PATIENTS WITH 
RECENT ONSET RHEUMATOID ARTHRITIS 
M.L.L. Prevoo, P.L.C.M. van Riel, M.A. van *t Hof, M.H. van Rijswijk, 
M.A. van Leeuwen, H.H. Kuper and L.B.A. van de Putte 
Chapter II 
Abstract 
Objective: This prospective longitudinal study evaluates the validity and reliability of 
joint counts (JCs) used to measure disease activity in patients with rheumatoid 
arthritis. 
Methods: From seven traditional JCs (Ritchie Articular Index (RAI), Modified RAI, 
Thompson score, 28 JC, 36 JC, total tender and total swollen joints) 37 "new" JCs 
were computed by considering three different characteristics of joint inflammation, 
tenderness, swelling, and the combination of tenderness and swelling, and by grading 
for tenderness and/or weighting for surface area of the joints. Several aspects of 
validity were investigated, the construct (correlation with radiographic damage), 
correlational (correlation with ESR, general health), and criterion validity (correlation 
with a Health Assessment Questionnaire, discrimination between high and low disease 
activity). 
Results: It was found that the validity and reliability of traditional JCs do not differ 
substantially. Graded JCs are almost always more valid than ungraded JCs. Weighted 
JCs are almost always less valid and reliable than unweighted JCs. 
Conclusion: No JC proved to be superior for measuring the disease activity under 
consideration. Taken simplicity into account the 28 JC, not graded and not weighted, 
was preferable. 
Introduction 
It is generally accepted that the assessment of joint involvement in rheumatoid 
arthritis (RA) is an important variable for evaluation of an individual patient's disease 
in daily clinical practice as well as in clinical trials. Joint involvement has the 
advantage over laboratory or radiographic information in that it gives an immediate 
indication of disease activity. A number of studies have analyzed how best to measure 
joint involvement, resulting in many different types of joint counts (JCs). Differences 
can result from the fact that a number of different abnormalities (or combinations of 
them) can be measured; tenderness, swelling, limitation of motion, pain on motion, 
deformity. JCs can also differ in the number of joints that are included, for example, 
the JC of Lansbury and Haut involved 86 joints,1 the Ritchie Articular Index (RAI) 53 
joints,2 and the JC developed by Fuchs et al.3 28 joints. At present no consensus exists 
on an optimal JC. In a recent review4 in which clinical trials were selected (clinical 
trials assessing the effectiveness of DMARD therapy published in English from 1986 
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through 1990), it appeared that JCs using tender joints, swollen joints or a combination 
of both were used often. Tender joint counts, in some studies graded for the severity 
of tenderness, were assessed in 30 of the 32 trials (94%). The most frequently used 
joint count was the Ritchie Articular Index or a modified Ritchie score (37% of the 
trials). Joint swelling was used as an endpoint in 21 trials (66%). In daily clinical 
practice a consistent measurement of joint involvement using JCs does not take place. 
Their use is hindered by complex calculations and the time taken to perform JCs. To 
resolve these problems new "more simple" JCs have been developed in several studies. 
Other studies have already evaluated several aspects of JCs: sensitivity to change, 
validity, reproducibility.3·5·6,7·8 As there is no standard to measure validity, different 
associations of JCs with disease variables have been investigated in several studies 
using cross-sectional data. In addition to these aspects simplicity and practicality 
should be taken into account. 
The goal of this prospective, longitudinal study was to evaluate JCs for validity 
and reliability in measuring disease activity in patients with recent onset of RA. 
Patients and methods 
Ninety-seven patients with recent onset RA who attended the outpatient 
department of the University Hospital of Nijmegen were followed monthly for three 
years. The study of these patients covered 1985-1991. Several variables were noted, 
some were assessed by specially trained research nurses, namely the number of tender 
joints (with the grading of the tenderness according to RAI), the number of swollen 
joints, and general health on a visual analogue scale of 100 mm (0=best possible, 
100=worst possible). Every three months it was recorded if a patient stopped, changed 
or started a drug (DMARD, NSAID).9,10 Laboratory tests included ESR according to 
Westergren (mm/1 hour), and C-Reactive Protein. Every six months patients completed 
a Health Assessment Questionnaire (HAQ).11 Plain anterior radiographs of the hands 
and feet were taken 6-monthly. The numbers of erosions and the joint space narrowing 
in the hands were scored by a modified version of Sharp's method. The foot 
radiographs were scored in a similar way.12 Summation of the erosions and joint space 
narrowing gave the total score. 
The joints which were examined, and the JCs used are shown in Table 1. The 
joints were examined for tenderness as well as for swelling. Swelling was not, 
however, measured for the cervical spine, temperomandibular, hip, subtalar and 
midtarsal joints. 
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Table 1. Definitions of the Joint Counts used tn this study* 
joint 
Cervical spine 
Sternoclavicular 
Acrom iocla vicular 
Temporomandibular 
Shoulder 
Elbow 
Wrist 
MCP (1) 
MCP (2-5) 
PIP (1-5) 
Hip 
Knee 
Ankle 
Talocalcaneal 
Midtarsal 
MTP(l) 
MTP (2-5) 
Total 
no of 
joints 
1 
2 
2 
2 
2 
2 
2 
2 
8 
10 
2 
2 
2 
2 
2 
2 
8 
53 
TOTT 
53 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
53 
TOTS 
44 
-
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
-
. 
+ 
+ 
44 
28 
JC 
-
-
-
-
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
-
-
-
-
-
28 
36 
JC 
-
-
-
-
-
+ 
+ 
-
+ 
+ 
-
+ 
+ 
-
-
+ 
+ 
36 
RAI 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
53 
TH 
-
-
-
-
-
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
-
-
+ 
+ 
38 
weigl 
4 
12 
4 
4 
45 
48 
32 
5 
5 
3 
82 
95 
32 
18 
25 
8 
3 
* TOTT=total of 53 tender joints, TOTS=total of 44 swollen joints, RAI=Ritchie Articular Index (the 
modified RAI is the RAI not graded and weighted), TH=Thompson Index; weights=weights for the 
surface area according to Thompson et al. 
Initially JCs previously described in the literature (traditional JCs) were analy-
sed. These were the RAI,2 the Modified RAI,8 the Thompson score (TH),6 the "total" 
of 53 tender joints (TOTT), the "total" of 44 swollen joints (TOTS), and the simplified 
joint counts developed by Egger et al.13 (the 36 JC), and Fuchs et al.3 (the 28 JC). If 
possible JCs were calculated for three abnormalities: tenderness, swelling, and a 
combination of tenderness and swelling. Tender joints could be measured graded (g) 
for pain, as described by the RAI (0=not tender, l=tender, 2=tender with wince 
response, 3=tender with wince and withdraw response) or not graded (no g, 
0=not tender, l=tender). The swollen joints were measured binary (0=not swollen, 
l=swollen). Tender joints (graded or ungraded) as well as swollen joints could be 
weighted for surface area (w or no w), following Thompson et al.6 and Lansbury and 
Haut.1 From the seven traditional JCs, the variations in grading and/or weighting led 
to the evaluation of 37 JCs. 
The validity of the JCs in measuring disease activity was examined. Because 
there is no standard to measure disease activity in RA, several aspects of validity were 
chosen for evaluation in all JCs."'15 The following were evaluated: the construct 
validity, which evaluates whether the process variable (disease activity) leads to the 
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ultimate result - the outcome. For this correlations between the individual patient's 
mean score of JCs with the progression of radiographic damage over the 3-year follow-
up period were calculated. The correlational validity: the correlation with other 
measures which are supposed to measure disease activity. Correlations of monthly 
assessments of JCs with the ESR and the general health on a visual analogue scale 
(VAS)(GH) were chosen to represent this form of validity. The mean of one person's 
correlations over a 3-year period are presented. The criterion validity: does the 
assessment fit with the theory about the disease? Does the method measure the true 
clinical status? Since disease activity will lead to functional impairment, we computed 
correlations with the HAQ. The mean of the individual's correlations are presented. In 
addition, the degree to which JCs discriminate between high and low disease activity 
was used. The moment of the rheumatologist's decision to start a DMARD or to stop 
DMARDs because of lack of efficacy was equated with high disease activity; 
withdrawal because of remission or not starting or changing DMARDs for at least one 
year, with low disease activity. Z-scores (top distance in terms of standard deviations) 
to discriminate between high and low disease activity for JCs were computed. 
All correlations were Pearson correlation coefficients. Variables which were 
not normally distributed could be transformed to normal. 
Finally, the reliability of the JCs was examined. The reproducibility was 
estimated using inter-period correlation matrix. For this the regression line of the 
intercorrelations with the intervening time (15 periods) was extrapolated to time 0. 
Index-total indices correlation were also calculated, as was Cronbach's alpha's to 
confirm internal consistency of the indices.16 
Results 
The characteristics of the patients at entry and after 3 years are described in 
Table 2. Disease activity according to the process-variables ESR and RAI was lower 
after 3 years than at entry, this is also true for the HAQ. Due to the cumulative 
character of the X-ray data, radiographic damage was higher after 3 years. Of the 97 
patients 83 (85.6%) were treated with DMARDs within the three year follow-up 
period. At the end of follow-up 66 patients were still using one of the DMARDs. 
The construct validity of the JCs is presented by the correlations of the mean 
score of JCs with the progression of radiographic damage (x-ray). Table 3 shows the 
Pearson correlations for tender, tender and swollen, and swollen JCs graded and/or 
weighted. JCs, as were the RAI, the Modified RAI (RAI not graded for tenderness,8 
23 
Chapter II 
Table 2. Characteristics of the patients. 
at entry after three years 
Female (%) 
age (years) * 
IgM-Rf+ (*5 IU/ml) (%) 
ESR" 
RAT 
Physical Disability* 
Erosions hand and feet* 
Narrowing hand and feet* 
61 
55 (45-65) 
80 
41 (22-67) 
12 (7-16) 
0.47 (0.16-1.13) 
1((M) 
0(0-3) 
— 
-
-
22 (10-35) 
4(2-11) 
0.28 (0.03-0.57) 
11 (2-20) 
7 (2-17) 
* Median (P25-P75). 
the Thompson score, total tender joints, and total swollen joints are indicated. The 28 
JC and the 36 JC are indicated if they were not graded and not weighted for all three 
variations of abnormalities. Comparing the traditional JCs (the indicated JCs) with each 
other for tender joints, the range of correlations is 0.15-0.19, for tender and swollen 
joints 0.20-0.25, and for swollen joints 0.29-0.33. 
Correlational validity is presented by the correlation coefficient of JCs with the 
process-variables ESR and general health on a VAS (GH) in Table 4. The correlations 
of the indicated JCs with ESR for tender, tender and swollen, and swollen JCs show 
the following ranges, respectively 0.28-0.32, 0.32-0.33, 0.28-0.30. For the correlations 
with GH the ranges are, respectively 0.30-0.33, 0.27-0.29, and 0.22-0.23. 
The correlations of the HAQ with JCs, a part of the criterion validity is 
presented in Table 5. The ranges between the correlations of indicated JCs are 0.43-
0.49,0.40-0.45, and 0.37-0.43, respectively. The degree of discrimination between high 
and low disease activity is also given in Table 5. A JC can discriminate well between 
high and low disease activity if the Z-score is high. The ranges between indicated JCs 
for tender, tender and swollen, and swollen JCs are respectively 1.52-1.68, 1.45-1.70, 
1.33-1.40. 
The influence of grading of tenderness and/or weighting for surface area was 
studied for all JCs. Only the influence of grading for the RAI vs the Modified RAI, 
the 28JC, and the 36 JC are presented in Tables 3-5. Of all correlations the maximal 
difference of graded vs. not graded JCs is 0.03, in favour of grading. Graded JCs, 
however, have lower Z-scores (maximal difference of 0.08). 
The influence of weighting is only presented for the 28 JC and the 36 JC. The 
correlations of tender and tender and swollen JCs have a maximal difference between 
weighted and non weighted JCs (Tables 3-5) of 0.06, in favour of no weighting. Only 
the correlations of the different JCs with the HAQ are in favour of weighting 
(maximum difference of 0.04). Correlations of swollen JCs are in favour of weighting 
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(maximum difference of 0.07). The ability of tender, tender and swollen, and swollen 
JCs to discriminate between high and low disease activity was decreased by weighting 
(the maximal difference between Z-scores was 0.32, in favour of no weighting). 
Another important aspect for tests is reliability. The reliability is presented 
through the reproducibility for time 0, the index-total indices correlations, and 
Cronbach's alpha's. The results of these were equal, therefore these single 
measurements were taken together as a mean value. These are presented in Table 6. 
The reliability is higher for JCs of tender joints. Grading of tenderness does not 
influence the reliability of the JCs. Weighting worsens the reliability of the JCs. 
Table 3. Evaluation of the construct validity of joint counts; mean correlations with radiographic damage, 
composed offender and/or swollen joints, graded and/or weighted* 
g w Tender Tender & Swollen Swollen 
RAI 
TH 
28 JC 
36 JC 
Total 
У 
η 
η 
У 
η 
У 
π 
У 
η 
У 
η 
η 
η 
η 
У 
У 
У 
η 
η 
У 
У 
η 
η 
η 
0.17 t 
0.15 Τ 
0.16 
0.12 
0.11 
0.17 
0.16 t 
0.16 
0.15 
0.20 
0.19 t 
0.18 t 
— 
— 
0.20 t 
0.17 
0.18 
0.22 
0.22 t 
0.19 
0.20 
0.25 
0.25 f 
— 
0.34 
0.31 
— 
0.30 
— 
0.29 t 
— 
0.31 
— 
0.33 t 
0.33 t 
* Pearson correlations; t traditional JCs; g=grading (yes or no), w=weighting (yes or no); RAI=Ritchie 
Articular Index, TH=Thompson Index, Total=total tender and total swollen joints. 
Discussion 
In this prospective longitudinal study, JCs were evaluated for their validity and 
reliability to measure disease activity in RA. Ninety-seven patients with recent onset 
RA were followed monthly in a standardized way for three years. Seven traditional 
JCs, already described in the literature, were evaluated. From these JCs 37 "new" JCs 
were computed by considering different characteristics of joint inflammation (namely 
tenderness, the combination of tenderness and swelling, and swelling), and by grading 
for tenderness and/or weighting for surface area of the joints. As it is not possible to 
measure disease activity in RA with one single standard the following previously 
published procedure was chosen to evaluate the validity of the different JCs. The 
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Table 4. Evaluation of the correlational validity offender and/от swollen joint counts; mean correlations 
•with ESR and general health (GH); graded and/or -weighted .* 
Tender Tender & Swollen Swollen 
g ESR GH ESR GH ESR GH 
RAI 
TH 
28 JC 
36 JC 
Total 
У 
η 
η 
У 
η 
У 
η 
У 
η 
У 
η 
η 
η 
η 
У 
У 
У 
η 
η 
У 
У 
η 
η 
η 
0.32 t 
0.29 f 
0.29 
0.31 
0.29 
0.33 
0.31 t 
0.30 
0.29 
0.31 
0.28 t 
0.29 t 
0.33 t 
0.31 t 
0.28 
0.29 
0.28 
0.32 
0.30 t 
0.29 
0.28 
0.32 
0.30 T 
0.32 1 
— 
0.33 t 
0.33 
0.32 
0.35 
0.32 t 
0.34 
0.33 
0.34 
0.33 t 
— 
— 
— 
0.27 f 
0.27 
0.26 
0.30 
028 f 
0.29 
027 
0.31 
0.29 t 
— 
0.30 
0.31 
— 
0.30 
— 
02% t 
— 
0.31 
— 
0.30 t 
0.29 t 
0.24 
0.25 
— 
02b 
— 
0.22 t 
— 
02Λ 
— 
022 t 
023 t 
* Pearson correlations; 1 traditional JCs; g=grading (yes or no), w=weightdng (yes or no); RAI=Ritchie 
Articular Index, TH=Thompson Index, Total=total tender joints, total swollen joints. 
Table 5. Evaluation of the criterion validity offender and/or swollen joint counts; mean correlations with 
Health Assessment Questionnaires (HAQ) andZ-scoresfor discrimination between high/low disease activity.* 
Tender Tender & Swollen Swollen 
8 HAQ Z-score HAQ Z-score HAQ Z-score 
RAI 
TH 
28 JC 
36 JC 
Total 
У 
η 
η 
У 
η 
У 
η 
У 
η 
У 
η 
η 
η 
η 
У 
У 
У 
η 
η 
У 
У 
η 
η 
η 
0.49 t 
0.48 f 
0.48 
0.46 
0.45 
0.44 
0.43 t 
0.48 
0.47 
0.46 
0.44 t 
0.47 
1.60 I 
1.68 t 
1.36 
1.32 
1.35 
1.57 
1.61 Τ 
1.33 
1.34 
1.48 
1.52 t 
1.60 t 
_ 
— 
0.45 î 
0.44 
0.44 
0.41 
0.40 t 
0.45 
0.44 
0.45 
0.43 t 
— 
— 
1.45 T 
1.30 
1.34 
1.62 
1.66 t 
1.39 
1.43 
1.66 
1.70 t 
— 
0.47 
0.47 
— 
0.44 
— 
0.37 t 
— 
0.46 
— 
0.41 t 
0.43 t 
_ . 
1.57 
1.33 
— 
1.36 
— 
1.33 t 
— 
1.31 
— 
1.40 t 
1.40 t 
Pearson correlations and Z-scores for the discrimination between high and low disease activity; 
t traditional JCs; g=groding (yes or no), w=weighting (yes or no); RAI=Ritchie Articular Index, 
TH=Thompson Index, Total=total of tender, swollen joints. 
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ТаЫе 6. Evaluation of the reliability offender and/or swollen Joint counts." 
g w Tender Trader & Swollen Swollen 
RAI 
TH 
28 JC 
36 JC 
Total 
У 
η 
η 
У 
η 
У 
η 
У 
η 
У 
η 
η 
η 
η 
У 
У 
У 
η 
η 
У 
У 
η 
η 
η 
0.87 Î 
0.87 Τ 
0.80 
0.77 
0.76 
0.86 
0.86 Î 
0.79 
0.79 
0.87 
0.87 î 
0.89 î 
— 
0.75 t 
0.73 
0.71 
0.84 
0.84 t 
0.75 
0.74 
0.84 
0.84 t 
— 
__ 
0.78 
0.74 
— 
0.71 
— 
0.81 t 
— 
0.74 
— 
0.82 t 
0.82 t 
* The reliability is presented by the mean value of the inter-period correlation of time 0, the index-total 
index correlation, and the Cronbach's alpha's; t traditional JCs; g=grading (yes or no), w=weighting 
(yes or no); RAI=Ritchie Articular Index, TH=Thompson Index, Total=total of tender joints, swollen 
joints. 
different aspects of validation known as construct, correlational, and criterion validity 
were investigated. Construct validity was represented by Pearson correlations of the 
mean score of JCs with the progression of damage shown by X-rays. Correlational 
validity was represented by correlations with ESR and GH, both measures being 
elements of the Disease Activity Score (DAS).17 Correlations with HAQ, and Z-scores 
(the discrimination between high and low disease activity) were taken to represent 
criterion validity. The reliability of the JCs was evaluated by the mean score of the 
reproducibility, index-total indices' correlation, and the Cronbach's alpha's. 
Only small differences were found when comparing the traditional JCs for the 
three aspects of validity (Tables 3-5) within the variations tenderness, swelling and the 
combination of tenderness and swelling. For the construct validity the highest 
correlations were found with JCs evaluating swelling of the joints. Earlier studies have 
also shown that the highest correlations with radiographic damage were found with JCs 
evaluating swelling. Combining swelling and tenderness produced correlations standing 
midway between the JCs evaluating tenderness and swelling alone. No substantial 
differences were found evaluating the correlational validity of the different JCs. 
Correlations with physical disability and the ability to discriminate between high and 
low disease activity (criterion validity) showed only small differences between the JCs. 
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Influence of grading and weighting 
In this study grading of tenderness almost always improved the validity and 
the reliability of the different JCs in measuring disease activity. The improvement, 
however, was very small. Several other studies have investigated whether grading is 
necessary for JCs to measure disease activity.3,6 However, no uniform conclusion could 
be drawn. Other aspects which should be taken into account when evaluating the 
necessity of grading are sensitivity of JCs to changes and the interobserver error. 
Grading of tenderness was specifically developed to improve the sensitivity of JCs to 
change. A recent study in which several clinical trials were included, concluded that 
graded or non-graded JCs gave similar results, there being no meaningful loss of 
sensitivity to change.18 Investigations of the interobserver error of graded vs not graded 
JCs show that grading is a source of interobserver error.8,19 
In contrast with the grading procedure, weighting almost always decreased the 
validity and reliability in this study. The study of Thompson et al. and of Fuchs et al. 
found that weighting increases the validity of JCs in measuring disease activity. 
However, in the study of Fuchs this improvement was not substantial and the study of 
Thompson correlated JCs only with serum C-Reactive Protein levels. Weighting 
decreases the sensitivity of JCs to change,18 and increases interobserver error.19 
In this study most JCs described in the literature were investigated in patients 
with recent onset RA. Whether our results would apply to patients with longer disease 
duration has to be investigated. Not included in this study are the ARA Articular 
Index, the Lansbury Articular Index, and the 70 JC as joint evaluation of the DIP 
joints of hands and feet were not included in our study. It remains to be seen whether 
inclusion of these joints is necessary in the evaluation of disease activity in patients 
with RA as it is known that OA changes in these joints could bias the results. This was 
the main reason for excluding these joints in the evaluation of radiographic damage 
in RA.20 Inclusion of these joints would also have resulted in an even more time 
consuming index. 
Two other studies have evaluated JCs for their validity in measuring disease 
activity. These are the study of Fuchs et al.3 (n=189, mean disease duration=12.9 
years), and Thompson et al.6(n=30, mean disease duration=15.5 years). These studies, 
however, use cross-sectional data and therefore did not consider the individual's disease 
pattern by calculating a mean value. Population characteristics of these two studies 
were similar to the presented characteristics (Table 2) of this study, apart from the 
number of patients and disease duration. In these studies several disease activity 
measures are correlated with JCs. In general the correlations presented in Table 3-5 for 
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JCs of tender joints or swollen joints were higher than those in the study of Fuchs et 
al. In the study of Thompson et al. JCs were only evaluated by correlations with the 
acute-phase response CRP. Almost all correlations with CRP found by Thompson were 
higher than the correlations found in this study for the three variations tenderness, 
tenderness and swelling, and swelling with ESR, with one exception, i.e. the original 
RAI. The differing methodologies of these studies, the use of cross-sectional and not 
longitudinal data, and the different number of patients is probably the cause of the 
variance in results. 
We conclude from the results of this longitudinal study that JC in which joints 
are graded for tenderness or weighted for surface area do not increase validity in 
measuring disease activity. The number of joints included in the JCs does not lead to 
a JC which is clearly superior to others for measuring disease activity for the aspects 
mentioned. Evaluating simplicity, after validity and reliability would result in the 
choice of the 28 JCs. The choice between 28 JCs composed of tender, tender and 
swollen, or swollen joints depends on the topic of the study. If the point of the study 
is radiographic damage the 28 JC for swollen joints should be chosen. For all other 
aspects the 28 JCs composed of tender or the combination of tender and swollen joints 
correlates well. 
Acknowledgements: We thank D. van den Akker, A. ter A vest, L. Theunisse, C. Versteegden for their 
assistance in data collection. 
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Chapter Ш 
Abstract 
Objective: An investigation of the reproducibility and validity of self-administered joint 
counts (JCs), measuring tenderness, swelling and the combination of both, in a 
longitudinal study. 
Methods: At the outpatient department a self-administration form, filled in by patients 
(SAJ-form), was used to measure joint involvement. Concurrent joint examinations 
performed by an assessor took place. The JCs and the scores of groups of joints of the 
assessors and patients were correlated. After the first SAJ-form (test) a retest was 
filled in (within 10 days) by the patients. Correlations between the JCs measured by 
the test and re test were computed to investigate the reproducibility. 
Results: The correlations between test and retest were high (>0.7). The correlations 
between the JCs and groups of joints measured by the assessors and by the patients 
was in the magnitude of 0.6. Correlations with other disease activity variables did not 
differ between the assessors' and patients' scores of the joint examination. 
Conclusion: In this study the joint examination performed by the patient was 
reproducible, however the correlation with the joint examination of the assessors was 
moderate. The value of the self-administered joint involvement needs further 
investigation and cannot yet replace the assessor's joint examination. 
Introduction 
Rheumatoid arthritis (RA) is a systemic illness with chronic, symmetric poly­
arthritis as its most important clinical feature. It is generally accepted that the clinical 
evaluation of joints is important for the evaluation of an individual patients' disease in 
daily clinical practice as well as in clinical trials.1 However, until recently no 
uniformity existed how to measure best joint involvement, resulting in the use of many 
different types of joint counts (JCs).2,3,4,5 Recently several JCs known in literature were 
evaluated for their validity and reliability to measure disease activity.6 It could be 
concluded that 28 JCs which measure the number of tender joints, swollen joints, or 
both tenderness and swelling were as valid and reliable as more comprehensive JCs 
(including more joints, and/or grading for tenderness, or weighting for surface area). 
Another study has shown that despite the simplification, these JCs were found to be 
sensitive to changes in clinical trials in which two groups were compared.7 Because 
of the validity, reliability, sensitivity and simplicity of these 28 JCs (measuring 
tenderness and/or swelling), the 28 JCs were chosen to be part of a validated standard 
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set of criteria for the assessment of activity and outcome of rheumatoid arthritis 
(EULAR Core set),8 and they were accepted as outcome measure in clinical trials by 
the American College of Rheumatology (ACR).9 More simple and even less time-
consuming to assess, would be a JC performed by the patient self comparable to the 
self-administration of pain on a visual analogue scale, and functionality by a 
questionnaire. The self-administration of joint involvement has already been 
investigated in five studies,10·11,12·13,14 each evaluating a different questionnaire, and a 
different JC. The goal of this study was to compare the validity and reproducibility of 
self-administered JCs to assess the disease activity of joints. 
Patients and methods 
Patients already included in a "follow-up study" (which started in 1985) of the 
Universities of Nijmegen and Groningen6,15 were asked to participate in this study. To 
be eligible to this follow-up study, patients with recent onset rheumatoid arthritis (RA) 
visiting the outpatient department of the Universities of Nijmegen (clinic 1) or 
Groningen (clinic 2) had to fulfil the following criteria: RA according to the 1987 
American College of Rheumatology (ACR) criteria, a disease duration less than one 
year, and not previously been treated with DMARDs. At the start of this study 173 
patients actually participated in the "follow-up study" in clinic 1 and 95 patients in 
clinic 2. These patients were seen by research nurses and rheumatologists at least every 
three months. 
In 1992, a self-administered joint evaluation form (SAJ) was developed. The 
SAJ-form consisted of two mannequins; one to evaluate swollen joints, and one for 
tender joints (this one is shown in Figure 1). The following joints, indicated by a 
circle, were evaluated bilaterally for tenderness and swelling: the shoulder, elbow, 
wrist, each metacarpal-phalangeal, each proximal interphalangeal of the fingers, in-
terphalangeal of the thumb, hip, knee, ankle, and each metatarsal-phalangeal. On all 
SAJ-form s instructions were included: patients were asked to indicate which joints 
were tender (graded, 0=no tenderness, l=slightly tender, 2=moderate tender, 3=severe 
tender) or swollen (not graded, 0=not swollen, l=swollen). The filling in of the first 
SAJ-form was under guidance, the instructions included in the test were explained. 
In clinic 1, the first SAJ-form (TEST) was filled in during a visit at the 
outpatient department under guidance of one observer (MP), who had no knowledge 
of the disease activity or joint involvement of the patients. Patients were asked to fill 
in another SAJ-form at home one day after the visit, and to return this SAJ by prepaid 
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mail (RETEST). The subsequent SAJs were mailed to the patients approximately 1 
week before their (three-monthly) visit to the outpatient department. These forms had 
to be filled in at the morning of the visit, and were collected by research nurses. In 
clinic 2, under guidance of research nurses or rheumatologists the first SAJ-form was 
filled in, before they performed a joint examination. Subsequent SAJs were filled in 
by the patients during the visits. 
Figure 1. The Self-administration form in which tender Joints should be indicated 
In both clinics, at the three monthly visits a complete joint examination of the 
same joints as mentioned above took place by research nurses or by rheum atologists 
(assessors). Tenderness was measured graded (0=not tender, l=tender, 2=tender with 
wince response, 3=tender with wince and withdraw response). Swollen joints were 
measured binary (0=not swollen,l=swollen). Other assessments were: pain on a visual 
analogue scale of 100 mm (Pain, 0=no pain, 100=worst pain possible), general health 
on a visual analogue scale (GH, 0=best possible, 100=worst possible), grip strength 
with a vigorimeter (mm Hg), erythrocyte sedimentation rate (ESR) according to 
Westergren. Every 6 months the patients completed a Health Assessment Questionnaire 
(HAQ).16 
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Table 1. The définitions of the JCs measured by assessors and by patients using SAJ forms.* 
joints no. of RAI THOM (weights) 28T 28 28S TOTT TOT TOTS 
joints T&S T&S 
Shoulder 
Elbow 
Wrist 
MCP (1-5) 
PIP(1-5) 
Hip 
Knee 
Ankle 
MTP (1) 
MTP (2-5) 
2 
2 
2 
10 
10 
2 
2 
2 
8 
2 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
. 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
(48) 
(32) 
(5) 
(3) 
(95) 
(32) 
(8) 
(3) 
+ 
+ 
+ 
+ 
+ 
-
+ 
-
-
-
+ 
+ 
+ 
+ 
+ 
-
+ 
-
-
-
+ 
+ 
+ 
+ 
+ 
-
+ 
-
-
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
* RAI=Ritchie Articular Index; THOM=Thompson Articular Score; 28T=28 JC measuring tender joints; 
28T&S=28 JC measuring the combination of tenderness and swelling; 28S=28 JC measuring swollen 
joints; TOTT=total number of tender joints; TOTT&S=total number of joints measuring the combination 
of tenderness and swelling; TOTS=total number of swollen joints. 
Several JCs were calculated of the scores of the assessors (assessors' JCs) as 
well as of the SAJ-forms filled in by the patients (SAJ-JCs). Some joints difficult to 
identify for the patients were excluded: temporomandibular, sternoclavicular, 
acromioclavicular, subtalar, midtarsal, and the cervical spine. The following JCs were 
calculated: modifications of the Ritchie Articular Index (RAI, 42 joints examined for 
tenderness (graded)), the total number of swollen joints (TOTS, 40 joints examined for 
swelling), total number of tender joints (TOTT, 42 joints examined for tenderness), 
total number of joints that are tender as well as swollen (TOTT&S, 40 joints), as well 
as the Thompson Count (THOM, 38 joints examined for the combination of tenderness 
and swelling, in which the joints were weighted for surface area), 28 Joint Count 
measuring tender joints (28T), swollen joints (28S), and the combination of tenderness 
and swelling (28T&S). Definitions of the JCs are shown in Table 1. 
Statistics 
The reproducibility of the SAJ-forms was determined by comparing the results 
of TEST versus RETEST (both patient-scores). After square root transformation of the 
JCs to obtain "normality", Pearson correlation coefficients between TEST- and 
RETEST-JCs were computed. 
To investigate the validity of the SAJ-JCs to measure the joint involvement, 
the assessors' JCs were chosen to be the golden standard. Systematic differences 
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between the JCs measured by the patients (SAJ) and the JCs measured by the assessors 
were tested by Wilcoxon signed rank tests (paired). To be able to control for 
systematic differences, regression analyses were performed. Pearson correlation 
coefficients between JCs of patients and assessors (golden standard) were computed. 
Results 
In clinic 1, 144 patients included in the "follow-up study" were asked to 
participate in this study. Of these patients three were not capable of filling in the SAJ 
form. A total of 141 patients (98%) did perform at least the first SAJ-form. After the 
first SAJ-form, a total of 327 SAJ-forms were send to these 141 patients of which 284 
(87%) returned. Because some SAJ-forms were not filled in correctly (for instance 
grading for tenderness was missing ), or the concurrent scores of the assessors were 
not available, a total of 386 SAJ-forms (91%) of all SAJ-forms (n=425) could be used 
for further analyses. Of the patients that performed the first SAJ-form (n=141), the 
number of retests that were completed within 10 days of the test was 111 (83%). At 
start of this study (the introduction of the first SAJ) the median disease duration of 
these 141 patients was 3.8 years (25%-75% interval: 2.8-5.3 years), the median age of 
these patients was 59 years (25%-75% interval: 51-67 years), 59% were female, and 
81% were IgM-Rheumatoid factor positive (IgM-Rf >10 IU). In clinic 2, 95 patients 
participated in this study and the total number of SAJ-forms was 229 (no retest). The 
median disease duration of these patients was 5.6 years (25%-75% interval: 4.4-6.3 
years), the median age of these patients was 56 years (25%-75% interval: between 
41-63 years), 69% were female, and 83% were IgM-Rf (>10 IU) positive. 
Correlations between TEST- and RETEST-JCs ranged from 0.77 up to 0.87. 
The correlations of the JCs measuring the combination of tenderness and swelling 
(THOM (0.77), 28T&S (0.78)) were lowest. 
For clinic 1 and 2, the median values of the JCs of the assessors and patients 
are shown in Table 2. All JCs except the 28JCs measuring swollen joints are 
significantly different (systematic difference) between the assessors and the patients 
(p-value Wilcoxon's signed rank tests less than 0.05). In both clinics an overestimation 
of the patient-JCs versus the assessors-JCs was observed. The Pearson correlation 
coefficients between the JCs measured by assessors (golden standard) and patients are 
presented in Table 3. The range of correlations of all JCs was 0.48-0.65 for clinic 1 
and 0.47-0.65 for clinic 2. Also correlations between observer JCs and SAJ-JCs for 
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three observers separately were computed (data not shown). These did not differ from 
the overall correlations. 
Table 2. The median values,and differences of the JCs (P10J4H)) measured by the assessors and patients.* 
JCs 
RAI 
THOM 
28T 
28T&S 
28S 
assessors' 
JCs 
3 (0,10) 
17 (0,193) 
2 (0,10) 
1 (0,7) 
5 (1,14) 
Nijmegen 
clinic 1 ( 
patients' 
JCs 
10 (0,26) 
57 (0Д88) 
7(0,24) 
3 (0,14) 
4 (0,16) 
a=386) 
median 
difference 
assessor-
patient 
-5 (-18,0) 
-16 (-212,38) 
-4 (-16,0) 
-1 (-8.2) 
0 (-7,7) 
p-value 
ρ < 0.01 
ρ < 0.01 
ρ < 0.01 
Ρ < 0.01 
ρ - 0.22 
assessors' 
JCs 
5 (0,18) 
5 (0,98) 
2 (0,13) 
1 (0, 6) 
2(0,11) 
Groningen 
clinic 2 ι 
patients' 
JCs 
5 (0, 21) 
12 (0,175) 
3 (0, 18) 
1 (0, 10) 
2 (0, 13) 
n=229) 
median 
difference 
assessor-
patient 
0 (-9. 5) 
0 (-136,32) 
0 (-7, 4) 
0 (-5. 1) 
0 (-6, 4) 
p-value 
ρ-0.02 
ρ < 0.01 
ρ < 0.01 
ρ < 0.01 
ρ = 0.07 
" p-values Wilcoxon signed rank test (paired); RAI=Ritchie Articular Index; THOM=Thompson Articular 
Score; 28T=28 JC measuring tender joints; 28T&S=28 JC measuring the combination of tenderness and 
swelling; 28S=28 JC measuring swollen joints. 
In order to identify whether the low correlations between the assessors (the 
golden standard) and patients could be explained by specific joints, the agreement 
between the assessors and patients was determined for groups of joints. To group the 
large number of joints, principal component analyses was performed separately for 
scores measuring swelling and tenderness (non-graded, binary) measured by patients 
and assessors. For both characteristics similar groups for the patients and assessors 
(Eigenvalue>l) were found. The following 7 groups could be formed: MCPs, PIPs, 
MTPs, and all large joints (wrists, ankles, knees, shoulders, elbows, hip). In further 
analyses these large joints (LJ) are grouped together. The reliability of the 4 groups 
measured by the assessors or patients both for tender and swollen joints was 
determined by Cronbach's alphas ranging from: MCP 0.84-0.92, PIP 0.87-0.93, MTP 
0.91-0.94, and LJ 0.58-0.86. The correlations (non-parametric, Spearman rank 
correlations) between the mean scores of the groups of joints scored by the assessor 
and by the patients are presented in Table 4. The correlation for swelling of the MTPs 
is low, and differs significantly (p<0.05) from the correlations of all other groups of 
joints. 
As low correlations were found between the assessors (golden standard) and 
the patients JCs and groups of joints, correlations of patients and assessors scores with 
other disease activity variables were computed. For this correlations between the scores 
of the groups of joints of the patients as well as of the assessors with ESR, Pain on 
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a visual analogue scale (Pain), general health on a visual analogue scale (GH), grip 
strength, and HAQ were computed. The results are presented in Table 5. All Spearman 
rank correlations of the groups of joints with these variables do not significantly differ 
between the assessors and the patients. Similar results were found if tenderness was 
graded (not binary). There were no differences in correlations between the two clinics. 
Table 3. Pearson correlations between the JCs measured by assessors and patients.' 
Nijmegen Groningen 
RAI 
THOM 
28T 
28T&S 
28S 
τοπ TOTT&S 
TOTS 
clinic 1 
n=386 
0.62 
0.48 
0.62 
0.56 
0.61 
0.65 
0.53 
0.51 
clinic 2 
n=229 
0.65 
0.47 
0.60 
0.61 
0.65 
0.60 
0.61 
0.64 
* RAI=Ritchie Articular Index; THOM=Thompson Articular Score; 28T=28 JC measuring tender joints; 
28T&S=28 JC measuring the combination of tenderness and swelling; 28S=28 JC measuring swollen 
joints; TOTT=total number of tender joints; TOTT&S=total number of joints measuring the combination 
of tenderness and swelling; TOTS= total number of swollen joints. 
Table 4. Spearman correlations between the groups of Joints measured by assessors and patients (clinics 
land2, n=615).* 
Spearman correlations between assessors and patients 
Tenderness Swelling 
MTP 
PIP 
MCP 
и 
0.48 
0.51 
0.50 
0.52 
0.25* 
0.56 
0.57 
0.54 
significantly (p<0.05) different from the other correlations. 
" LJ=group of joints including wrists, ankles, knees, shoulders, elbows, hip. 
Discussion 
In the assessment of disease activity in patients with RA, an increase in the use 
of self-administration forms, like questionnaires to assess functionality, visual analogue 
scales to measure pain, general health, and global disease activity, is seen. In recent 
years, also the self-administration of joint involvement measured by different self-
40 
Self-administered joint counts 
administration forms and JCs10·11'12,13,14 has been evaluated. Although an attempt was 
made to test the validity of these different SAJ-JCs to measure the assessors' JCs, a 
comparison between different available SAJ-JCs has never been performed. In this 
study available SAJ-JCs, including 28 JCs as it was recently shown that these JCs are 
reliable and valid measurements to assess disease activity,6 were evaluated in a large 
cohort of patients with RA. 
In view of the accessibility of the SAJ-forms the response rate to the SAJ-form 
was high. Almost all patients were capable of filling in the SAJ-form correctly, 
therefore the number of SAJ-forms that could be used in the analyses was high. 
The reproducibility of the self-administered JCs appeared to be satisfactory, 
and is comparable to test-retest correlations of other assessments.,6·17·18 
Table 5. Spearman rank correlations between the groups of joints of patients and assessors (patient-
assessor) with other disease activity variables.1' 
ESR PAIN GH GRIP HAQ 
(n=±615) (n=±615) (n=±386) STRENGTH (n-±190) 
(n= ±615) 
Tenderness: 
MTP 
PIP 
MCP 
U 
Swelling: 
MTP 
PIP 
MCP 
U 
patient 
0.01 
0.11 
0.08 
0.06 
0.07 
0.02 
0.06 
0.07 
assessor 
0.12 
0.14 
0.16 
0.17 
0.03 
0.09 
0.14 
0.21 
patient 
0.34 
0.39 
0.43 
0.50 
0.28 
0.22 
0.33 
0.38 
assessor 
0.23 
0.35 
0.36 
0.44 
0.23 
0.29 
0.35 
0.32 
patient 
0.36 
0.38 
0.41 
0.45 
0.23 
0.18 
0.24 
0.28 
assessor 
0.25 
0.35 
0.36 
0.36 
0.14 
0.15 
0.13 
0.19 
patient 
0.20 
0.27 
0.33 
0.32 
0.10 
0.23 
0.26 
0.31 
assessor 
0.20 
0.27 
0.26 
0.34 
0.22 
0.25 
0.24 
0.33 
patient 
0.32 
0.37 
0.42 
0.50 
0.16 
0.19 
0.21 
0.39 
assessor 
0.37 
0.37 
0.29 
0.39 
0.18 
0.15 
0.14 
0.24 
* ESR=erythrocytc sedimentation rate; PAIN=visual analogue scale measuring pain; GH=visual analogue 
scale measuring general health; HAQ=Health Assessment Questionnaire; LJ=group of joints including 
wrists, ankles, knees, shoulders, elbows, hip. 
However, the validity of SAJ-JCs with respect to the assessors' JCs is low. The 
low correlation could not be explained by differences in the number of joints, in 
weighting of joints, and/or grading of tenderness (comprehensive JCs did as bad as 28 
JCs). The way the SAJ-form was introduced and explained to the patients did not lead 
to any difference (clinics 1 and 2). Finally no group of joints could be indicated to 
explain these low correlations. If the purpose of a self-administration is to replace an 
assessors' score, a correlation between these scores should be high (higher than 0.9 and 
for systematic differences a correction should be possible, they should be almost 
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identical). Therefore on the basis of the results of this study it can be concluded that 
the joint involvement measured by assessors cannot be replaced by the self-
administered scores of the patients. In four of the five studies in which self-
administered JCs were evaluated it was concluded that the validity of the self-
administration JCs to measure the assessors' JCs was good,10,11,12,13 despite the fact that 
the correlations in these studies are in the magnitude of 0.40-0.89. The only study in 
which it was concluded correctly that the validity to assess assessors' JCs was low was 
the study of Hewlett et al.14 In general it can be concluded that the results of these 
studies are comparable to this study. 
Due to the low validity to assess the assessors' scores, the relation of the self-
administered scores with some other disease variables was computed. The relation of 
the SAJ-scores with these disease variables did not differ from the assessors' scores. 
It can be concluded that the reproducibility of the self-administration of the 
joint involvement was good in this population. The agreement between health 
professionals and the patients was low, for JCs as well as for groups of joints. The 
relation of the self-administered groups of joints with other disease variables, however, 
did not differ from the assessors' scores. 
Therefore the self-administered joint involvement cannot yet replace the joint 
examination by health professionals. Further studies should take place to investigate 
the place of these self-administered measurements of joint involvement in the 
assessment of RA. 
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Chapter IV 
Abstract 
Objective: The development and validation of Modified Disease Activity Scores that 
include different 28 Joint Counts (28 JCs). 
Methods: These scores were developed by canonical discriminant analyses and 
validated for criterion, correlational, and construct validity. The influence of disease 
duration on the composition of the DAS was also investigated. 
Results: No influence of disease duration was found. The Modified Disease Activity 
Scores that include 28 JCs were able to discriminate between high and low disease 
activity (as indicated by clinical decisions of rheumatologists). 
Conclusion: The Modified Disease Activity Scores are as valid as Disease Activity 
Scores that include more comprehensive JCs. 
Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory disease that is known to 
cause pain, disability, and joint destruction. Both in daily clinical practice and in 
clinical trials many variables are recorded to monitor the course of the disease. Since 
an evaluation of disease activity by single variables leads to methodological 
problems,1,2 several indices consisting of more than one variable have been 
developed.3'4,5,6 One of these indices is the Disease Activity Score (DAS), which was 
developed and validated by our group in patients with recent onset RA.5,7 The DAS 
includes two comprehensive joint counts (JCs), i.e. the Ritchie Articular Index (RAI)8 
and the total number of swollen joints, plus the erythrocyte sedimentation rate (ESR), 
and general health (GH) assessment on a visual analogue scale (VAS). Recent studies 
have indicated that joint counts consisting of 28 joints (28 JCs) are as valid and 
reliable as more comprehensive joint counts.9,10 Herein we describe the development 
and validation of Modified Disease Activity Scores that include different 28 JCs, 
measuring tenderness, swelling, or both. 
Patients and methods 
Patients with recent onset RA, who attended the outpatient department at the 
University Hospital Nijmegen (clinic 1) or University Hospital Groningen (clinic 2) 
were eligible for this study if they had RA according to the American College of 
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Rheumatology criteria (ACR);11 had a disease duration of less than one year; had not 
been previously treated with Disease Modifying Anti-Rheumatic Drugs (DMARDs). 
Between 1985 and 1994, 227 patients from clinic 1 and 94 patients from clinic 2 took 
part in the study. 
In both clinics, patients were seen by research nurses and by rheum atologists 
at least once every three months. The following parameters were assessed: pain (Pain) 
and general health (GH), all on a visual analogue scale of 100 mm (VAS), morning 
stiffness, grip strength, Westergren erythrocyte sedimentation rate (ESR), thrombocyte 
count, and levels of haemoglobin, albumin, αϊ-globulin, oc2-globulin, ß-globulin, and 
γ-globulin. The following joint counts were calculated: RAI, total number of tender 
joints (53 joints), total number of swollen joints (TOTS [44 joints]), and 28 Joint 
Count measuring tender joints (28T), swollen joints (28S), and joints that are both 
tender and swollen (28T&S).9·12 Data on medication including whether patients had 
stopped, changed or started with a DMARD, or a Non-Steroidal Anti-Inflammatory 
Drug (NSAID) were also collected. Every 6 months patients completed a Health 
Assessment Questionnaire (HAQ).13 Plain anterior radiographs of the hands and feet 
were obtained at least once every 3 years and were scored for the number of erosions 
and joint space narrowing by a modified version of Sharp's method.14 In clinic 2 
sufficient data on medication, GH, and HAQ were not available. 
The construction of Disease Activity Scores (clinic 1) 
One of the most important aspects of a Disease Activity Score is the ability 
to discriminate between high and low disease activity. Similar to the study in which 
the original DAS was developed,5 the development of Disease Activity Scores in this 
study was based on disease activity as indicated by the clinical decisions of clinic 1 
rheumatologists. A high level of disease activity was defined as the time at which 
rheum atologists decided that the patient should start DMARD treatment, or that the 
DMARD being used should be changed after a wash out period of longer than 1 month 
for sulphasalazine or methotrexate, and longer than 2 months for hydroxychloroquine, 
aurothioglucose, D-penicillamine, or azathioprine. The periods of low disease activity 
were defined as the time the rheumatologists decided that DMARD treatment should 
be stopped because of remission, or periods of at least one year during which DMARD 
treatment was not started, or existing DMARD treatment was not changed. Apparent 
periods of low disease activity were checked in the medical records for specific 
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information of the rheumatologists' decision (non-compliance, refusal of therapy etc.). 
In the analyses two periods of high and two periods of low disease activity per patient 
with a time-period longer than 1 year were randomly chosen. To obtain "normality" 
the variables were transformed. 
The original DAS was developed and validated in these patients during the 
early phase of RA, the validity in patients with longer disease duration has not yet 
been studied. In the present study, the development of the DAS was done using both 
patients with early disease and patients with established disease. In these analyses only 
comprehensive joint counts (RAI, total number of tender joints, and total number of 
swollen joints) were initially included, and principal components analysis (factor 
analysis) was performed to group the large number of variables (complete data set). 
The newly developed Disease Activity Score was obtained from canonical discriminant 
analysis and from logistic discriminant analysis. To investigate the influence of disease 
duration on the ability to discriminate, we divided the data according to two different 
disease durations: patients with short disease duration (<3 years), and those with longer 
disease duration (¿3 years). Principal components analyses (factor analyses), and 
canonical discriminant analyses were also performed according to these groupings 
(DASshort, DASlong). 
In a second step, the comprehensive JCs included in the newly developed 
Disease Activity Score were replaced by 28 JCs. The discriminant function, and 
canonical correlations of these Modified Disease Activity Scores (in which the 28T 
JCs, the 28S JC, and the 28T&S JC are included) were computed by canonical 
discriminant analyses and by logistic discriminant analyses. 
Validation of the Disease Activity Scores (clinics 1 and 2) 
For the validation of the Disease Activity Scores, data collected in Nijmegen 
(clinic 1) as well as in Groningen (clinic 2) were used. Since there is no single 
standard to measure disease activity several aspects of validity have to be evaluated.13 
We chose three aspects: criterion validity (does the assessment fit with the theory 
about the disease; does the method measure the true clinical status), correlational 
validity (correlations with other measures which are supposed to measure disease 
activity), and construct validity (does the process variable lead to the ultimate result; 
the outcome). 
Criterion validity was examined by means of the correlations between the 
individual's Disease Activity Scores and functional impairment (HAQ score and grip 
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strength). For correlational validity correlations between the different Disease Activity 
Scores, and between Disease Activity Scores and other indices of disease activity3,4 
were calculated, since it has been previously shown that the correlational validity of 
indices is substantially higher than that of single variables.7 For construct validity, the 
areas-under-the-curves of the Disease Activity Scores were correlated with the increase 
in radiographic damage. Because radiographs were obtained at least once every three 
years, 3 disease periods, i.e. 0-3 years, 3-6 years, and 0-6 years were analyzed. 
Results 
Of the 227 patients from clinic 1, 64% were female, the median age at the start 
of the study was 55 years, and 78% were IgM-Rheumatoid factor (IgM-Rf)(>10 IU) 
positive. Of the 94 patients of clinic 2, 66% were female, their median age was 51 
years, and 84% were IgM-Rf positive. For the development of Disease Activity Scores, 
142 patients with 189 periods of high disease activity and 56 patients with 90 periods 
of low disease activity were selected. 
Disease Activity Scores in early and established disease 
Initially, principal components analysis was performed, resulting in 5 factors 
with an Eigenvalue of more than 1. The factors can be described as "laboratory 
measures", "semi-objective clinical scores" (JCs), "functional status measures" (grip 
strength), "subjective assessments by the patients" (Pain, GH, morning stiffness), and 
"ß-globulin and γ-globulin". To select the variables that best discriminate between 
high and low disease activity, canonical discriminant analysis was performed on all 
variables. This resulted in a discriminant function of 9 variables (Pain, haemoglobin, 
ESR, grip strength, morning stiffness, TOTS, RAI, ß-globulin and oc2-globulin) with 
a canonical correlation of 0.81 (DAS with 9 variables). These 9 variables loaded on 
the factors of the principal components analysis. The four variables RAI, TOTS, ESR, 
GH (elements of the original DAS) were also analyzed by canonical discriminant 
analysis. This resulted in a function with a canonical correlation of 0.81 (DASnew). 
Since canonical correlations of the DAS with 9 variables and the DASnew (based on 
4 variables) were equal, we decided to use the four variables of the DASnew in further 
analyses. 
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To evaluate the influence of disease duration, principal components analyses 
were performed for two groups: disease duration short (<3 years) and longer disease 
duration (¿3 years). The 5 factors identified in the longer disease duration were 
identical to the 5 factors resulting from the complete data set, mentioned above. For 
the short disease duration group the variables were grouped into 4 factors: the factor 
"functional status measures" (grip strength) was included in the factor "semi-objective 
clinical scores". Because the DASnew could discriminate well, canonical discriminant 
analyses with the four elements of the DASnew were performed for both groups and 
resulted in similar canonical correlations of 0.77 and 0.75. The relationships between 
the different Disease Activity Scores (original DAS, DASnew, DASshort, and 
DASlong) were evaluated by intercorrelations (Pearson). These were all higher than 
0.95. Therefore it can be concluded that disease duration did not influence the 
composition of the Disease Activity Scores. 
Table 1. Modified Disease Activity Scores and DASnew with assessment of general health (GH) developed 
by canonical discriminant analyses, and the Modified Disease Activity Scores without assessment of GH, 
predicted from the scores with GH by regression analyses.* 
canonical 
correlation Disease Activity Scores 
DAS new: 
with GH 0.81 0.54 v7 RAI + 0.039 TOTS + 0.72 In ESR + 0.013 GH 
without GH (0.54 V RAI + 0.039 TOTS + 0.72 In ESR) * 1.08 + 0.14 
DAS28 T+S: 
with GH 0.82 0.56 v7 28T + 0.28 V 28S + 0.70 In ESR + 0.014 GH 
without GH (0.56 V28T + 028 v^eS + 0.70 In ESR) " 1.08 + 0.16 
DAS28 T&S: 
withGH 0.81 0.73 v'28T&S +0.76 In ESR+ 0.016 GH 
without GH (0.73 v^eT&S + 0.76 In ESR) * 1.085 + 0.24 
* DAS 28T+S-DAS including 28 JC measuring tender joints and 28 JC measuring swollen joints; 
DAS28T&S=DAS including 28 JC measuring both tenderness and swelling; RAI=Ritchie Articular Index; 
TOTS=total number of swollen joints (n=44); ESR=erythrocyte sedimentation rate; GH=general health 
on a visual analogue scale; 28T=28 JC measuring tender joints; 28S=28 JC measuring swollen joints; 
28T&S=28 JC measuring joints which are tender and swollen. For the development of the Scores without 
GH, the constant is chosen in such a way that the mean difference with the DAS-score including GH is 
zero. 
Modified Disease Activity Scores 
In the next step the two comprehensive joint counts were replaced by 28 JCs. 
Discriminatory functions, and the canonical correlations of the Modified Disease 
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Activity Scores are presented in Table 1. The coefficients of the functions of the 
Modified Disease Activity Scores and the DASnew could not easily be compared 
because the variables were highly interrelated. The canonical correlations did not 
differ. The correlation of both Modified Disease Activity Scores with the DASnew was 
0.97. Discriminatory functions were also assessed by logistic discriminant analyses. 
The functions resulting from these analyses were correlated with the functions resulting 
from canonical discriminant analyses (DASnew, DAS28T+S, DAS28T&S). All Pearson 
correlations between them were higher than 0.99. 
Table 2. Validation (criterion, construct) of Disease Activity Scores with Health Assessment Questionnaires 
scores (HAQ), and grip strength (meanfSEM) of individual patients' Pearson correlation coefficients), and 
with radiographic damage (number of erosions, joint space narrowing, total score) (correlations of the area-
under-the-curve of the Disease Activity Scores with the increase in radiographic damage for the time-period 
0-6 years).* 
DASnew DAS28T+S DAS28T&S 
HAQ clinic 1 (n=131) 
Grip Strength: 
clinic 1 (n=166) 
clinic 2 (n=91) 
Radiographic Damage 
clinics 1 and 2: 
number of erosions (n=89) 
joint space narrowing (n=89) 
total erosions + narrowing (n=89) 
0.39(0.038) 
-0.32(0.029) 
-0.32(0.036) 
0.46 
0.49 
0.49 
0.38(0.039) 
-0.34(0.029) 
-0.30(0.036) 
0.47 
0.51 
0.51 
0.38(0.039) 
-0.34(0.028) 
-0.29(0.035) 
0.50 
0.52 
0.53 
» DAS 28 JC T+S=DAS including 28 JC measuring tender joints and 28 JC measuring swollen joints; 
DAS 28 T&S=DAS including 28 JC measuring both tenderness and swelling. 
Validation of the Disease Activity Scores 
For the validation of the DASnew and the Modified Disease Activity Scores 
in clinic 1 and clinic 2, Disease Activity Scores without GH (data not available from 
clinic 2) were predicted from the scores with GH (by regression). The functions are 
presented in Table 1. The standard deviations of the differences between the DAS 
without GH versus the DAS with GH (accuracy) were of the magnitude of 
0.3 (DASpoints). Table 2 shows the mean of the individual patients' Pearson 
correlations between HAQ and Disease Activity Scores (clinic 1) or between grip 
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strength and Disease Activity Scores (clinics 1 and 2) (criterion validity). Similar 
correlations for the three Disease Activity Scores with HAQ or grip strength were 
found. Correlational validity was investigated by the correlations between DASoriginal, 
DASnew, DASshort, and DASlong, these were all higher than 0.95. Correlations 
between the DASnew, DAS28T+S, and DAS28T&S were all higher than 0.94. 
Correlations of all scores with the Mallya index and the van Riel index were of the 
magnitude of 0.80. For construct validity, data on radiographic damage for the disease 
period 0-3 years were available for 165 patients, and data on radiographic damage for 
the period 3-6 years were for 92 patients available. Only the correlations for the time-
period 0-6 years are shown in Table 2, since there was no significant difference 
between correlations for each of the 3-year time-periods and the 6-year overall period. 
Discussion 
Indices of disease activity such as the Disease Activity Scores were developed 
to enable evaluation of disease activity in individual patients as well as in clinical trials 
with minimization of methodologie problems.1'2 The original DAS was developed in 
patients with early onset RA, and includes two comprehensive JCs. In the present 
study the development and validation of Disease Activity Scores took place in patients 
with early disease as well as more established disease. Besides a Disease Activity 
Score with 9 variables, the DASnew (with the same elements as the original DAS) 
appeared to discriminate well and was preferable because of its clinical simplicity. In 
the development of the Disease Activity Scores the rheumatologists' decisions about 
treatment strategies were used as the outside standard for determining a patients's 
disease status. This was a valid method since the rheum atologists were unaware that 
their decisions were part of this study, and although the original DAS had already been 
developed, the decisions of the rheum atologist could not be based on those Scores 
since the ESR-value (part of the original DAS) was not available at the time of the 
rheum atologists' treatment decision. 
The original DAS was developed in patients with early RA only. In the present 
study an investigation of the influence of disease duration on the ability to discriminate 
between high and low disease activity was performed. The 5 factors resulting from the 
principal components analysis of the complete data set were comparable with the 
factors identified in an earlier study.3 The different results for the short disease 
duration group with respect to the grip strength variables (functionality measures) can 
be explained by the fact that grip strength reflects not only disease activity (process 
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variable) but also (irreversible) destruction (outcome variable), which will develop after 
a lag-time. The canonical correlations for the two groups with different disease 
durations were similar; therefore no influence of disease duration on the structure of 
the Disease Activity Scores was observed. 
In this study the results of the canonical discriminant analyses, and logistic 
discriminant analyses were similar between the DASnew and the Modified Disease 
Activity Scores. Therefore it can be concluded that the Modified Disease Activity 
Scores including 28 JCs discriminate just as well between high and low disease 
activity as do the Disease Activity Score that include comprehensive JCs. The 
Modified Disease Activity Scores were also validated for several features (criterion, 
correlational, construct). Taking all these validity features together, it can be concluded 
from this study that the Modified Disease Activity Scores are as valid as the DASnew. 
Since the development of the original Disease Activity Score (which was done 
using discriminant analysis including factor values and multiple regression) differed 
from the development of the DAS mentioned in this study (done using canonical 
discriminant analysis), the functions of the original DAS cannot be compared with the 
functions described herein. In this study, in addition to the canonical discriminant 
analyses, logistic discriminant analyses were also performed, however since these 
logistic functions correlated very highly with the canonical discriminant functions only 
the functions resulting from the canonical discriminant analyses were presented. 
Another characteristic of the Disease Activity Scores, that should be investi-
gated is the sensitivity to change. This could not be evaluated in the present study, 
which used prospective data from daily clinical practice. According to Fuchs et al. the 
original DAS can discriminate between active drug and placebo treated patient 
groups.16 One element of the original DAS is the RAI, in which joints are graded for 
tenderness. Grading of tenderness was specifically developed to improve the sensitivity 
of JCs to change. However, in a recent study in which several clinical trials were 
included, it was shown that reduced JCs did not decrease the ability to detect changes 
over time (sensitivity to change).10 Therefore it is not expected that the sensitivity of 
the Modified Disease Activity Scores would differ from that of the original DAS, 
although this must be investigated in further studies. 
From the results of this longitudinal study it can be concluded that disease 
duration does not influence the composition of the Disease Activity Score. However, 
further research should be performed to determine whether the Disease Activity Scores 
can discriminate in patients with longer disease duration than that of the patients 
included in this study. Disease Activity Scores including 28 JCs can discriminate 
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between high and low disease activity as well as a Disease Activity Score with more 
comprehensive JCs. The validity of Modified Disease Activity Scores is comparable 
with that of Disease Activity Scores that include comprehensive JCs. The two 
Modified Disease Activity Scores, shown in Table 1, are similar in their ability to 
discriminate and their validity. Preference for the JCs to be included will lead to a 
choice between them. 
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Abstract 
Objective: To develop and validate response criteria based on an index of disease 
activity. 
Methods: Development. Response criteria based on the Disease Activity Score (DAS) 
were developed in an open study of recent onset RA patients. Response was defined 
to be a combination of significant change from baseline and the level of 
attaineddisease activity according to rheumatologists' treatment decisions. Validation. 
In a trial (n=60) comparing HCQ and S ASP, construct (x-ray progression), criterion 
(HAQ), and discriminant validity were studied for EULAR, ACR, and WHO/ILAR 
response criteria. 
Results: Development. Good response was defined as a significant decrease in DAS 
(>1.2) and low disease activity left (¿2.4). Non response was defined as a decrease 
¿0.6, or a decrease >0.6 and ¿1.2 with an attained DAS >3.7. The remaining patients 
were moderate responders. Validation. EULAR response criteria were significantly 
associated with x-ray progression and HAQ, and could discriminate between SASP and 
HCQ. ACR and WHO/ILAR criteria were associated with HAQ-score, but not with x-
ray progression. They did not discriminate between HCQ and SASP. 
Conclusion: EULAR response showed better construct, criterion, and discriminant 
validity than ACR and WHO/ILAR response. 
Introduction 
Rheumatoid arthritis (RA) is a chronic systemic disease, with poly-arthritis as 
the main feature. Chronic inflammation of the joints often leads to radiographic 
detectable joint damage and functional impairment. Because the pathogenesis of RA 
is still unknown, anti-rheumatic therapies are focused on nonspecifically suppressing 
disease activity. Patients with RA have various manifestations of the disease, therefore 
disease activity cannot be expressed by a single parameter of inflammation. An index 
of disease activity should combine measurements representing several aspects of the 
disease.1 The Disease Activity Score (DAS) is such a validated index, combining 
Ritchie Articular Index,2 number of swollen joints, erythrocyte sedimentation rate, and 
general health.3 
In general the efficacy of treatments is studied by comparing group means of 
(change in) disease activity variables. However, a significant difference between 
groups does not indicate the number of patients actually responding to treatment. 
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Therefore, in addition to disease activity, response of individual patients to anti-
rheumatic therapy is an important measurement both in daily clinical practice and in 
trials. Response criteria should include a relevant change in disease activity since start 
of treatment, and the attained level of disease activity during follow-up.4 
On behalf of the EULAR Standing Committee for International Clinical 
Studies including Therapeutic Trials, it was decided to develop response criteria based 
on a disease activity index taking into account its measurement error, and to 
investigate construct, criterion, and discriminant validity in a different group of 
patients. The validity of these response criteria was compared with the preliminary 
ACR criteria for improvement,5 and with the proposed WHO/ILAR criteria for 
decreased inflammatory synovitis.6 
Patients and Methods 
Development of response criteria 
Patients and measurements. Response criteria were developed in a cohort of 
patients with recent onset RA (<1 year) according to the American College of 
Rheumatology criteria,7 attending the outpatient department at the University Hospital 
Nijmegen. Between 1985 and 1994, 227 patients were included in the study. Slow-
Acting Anti-Rheumatic Drugs (SAARDs) were prescribed when treatment with Non-
steroidal Anti-Inflammatory Drugs (NSAIDs) alone was not sufficiently effective. 
Sulphasalazine, hydroxychloroquine, or auranofin were regarded as first option 
SAARDs. In case of treatment failure aurothioglucose or methotrexate could be 
prescribed. A third option was treatment with D-penicillamine or azathioprine. Oral 
prednisone (10 mg) and intra-articular steroid injections were allowed as adjuvans. 
Rheumatologists decided about change in therapy. 
Patients were seen every 3 months by specially trained research nurses. They 
collected clinical and laboratory data, including: Ritchie Articular Index (RAI), number 
of swollen joints (TOTS), erythrocyte sedimentation rate (ESR, mm/h), and general 
health (GH, on a visual analogue scale of 100 mm). On the basis of these 
measurements the Disease Activity Score (DAS)3 can be calculated as: 
DAS = 0.54 i/RAI + 0.065 TOTS + 0.33 In ESR + 0.0072 GH 
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The measurement error of the DAS was estimated using interperiod correlation 
matrix analysis (IPC) in patients with i3 year follow-up (n=78). The corresponding 
regression line (y-axis: interperiod Pearson correlations between DAS measurements, 
x-axis: intermediate time interval) was used for the estimation of the measurement-
remeasurement correlation r0 as the intercept of the regression line (correlation 
between DAS measurements with intermediate time interval=0).8 From this r0 the 
measurement error (e) may be calculated: 
e2/sdl=(l/r,)-l 
(sd=standard deviation of the DAS). 
Definition of response. Response was defined to be composed of both: 
a) change in disease activity from baseline and b) the level of disease activity attained. 
The following criteria for change and attained disease activity were used: Ad a. For 
good response a statistically significant decrease in disease activity from baseline, i.e. 
larger than two times the measurement error (2e), was obligatory. Ad b. For good 
response the attained DAS-level must correspond with low disease activity. Periods of 
low disease activity were defined as the time the rheumatologists recommended that 
S AARD treatment be stopped because of remission, or periods of at least 1 year during 
which SAARD treatment was not started, or existing SAARD treatment was not 
changed. A high level of disease activity was defined as the time at which the 
rheum atologists decided that the patient should start SAARD treatment, or that the 
SAARD being used should be changed (after a washout period of >1 month for 
sulphasalazine or methotrexate, and >2 months for the remaining SAARDs). Medical 
records were checked to correct for reasons other than high or low disease activity that 
could bias the rheum atologists' decision regarding treatment (noncompliance, refusal 
of therapy, etc.). In the analyses, 2 periods of high and 2 periods of low disease 
activity per patient, with a time period between high and low activity of more than 1 
year, were randomly chosen. 
Validation of response criteria 
Patients and Measurements. In a 48-week double-blind trial comparing 
sulphasalazine (SASP) and hydroxychloroquine (HCQ) in 60 recent onset RA patients,9 
the EULAR response criteria and two other newly developed response criteria, i.e. the 
WHOALAR and the ACR criteria (Table 1) were validated. Disease activity variables 
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were measured every 4 weeks. X-rays of hands and feet were taken at baseline, at 24, 
and 48 weeks. X-rays were scored with a modified Sharp method.10 At week 0,12,24, 
36, and 48 a Dutch equivalent of the Stanford Health Assessment Questionnaire 
(HAQ) was used to measure functional capacity11 in the last 41 consecutive patients 
of the trial. 
Table 1. Response criteria defined by WHO/ILAR and ACR. 
WHO-ILAR response criteria ACR response criteria 
1. >20% improvement in swollen joint count 1. ¿20% improvement in swollen joint count 
2. >20% improvement in tender joint count, or 2. 220% improvement in tender joint count 
i 5 if the count is between 16 and 20 
3. >20% improvement in at least 2 of the 3. ¿20% improvement in at least 3 of the 
following 3 measures: following S measures: 
a. patients' or physicians' global a. patients' global disease activity 
disease activity b. physicians' global disease activity 
b. pain c. patients' assessment of pain 
c. ESR d. acute phase reactant 
e. disability 
Response was retrospectively assessed every 4 weeks with the newly 
developed criteria based on the DAS, and with the WHO-ILAR response-criteria.6 
Because physical disability (HAQ) was measured less frequently, response with the 
preliminary ACR criteria was assessed every 12 weeks.5 The physicians' global disease 
activity assessment was not included in the original trial. Therefore we decided that, 
instead of three out of five, patients had to fulfil three of the four remaining measures 
apart from improvement in tender and swollen joint count to be a responder. 
Validation procedures. Concurrent validity was studied by comparing 
response classified by ACR and WHO/ILAR criteria with the EULAR response 
categories at weeks 12, 24, 36, and 48. Construct validity is an aspect of validity 
investigating the association of the criteria with the expected results, the outcome. The 
association between response and x-ray progression (total number of new erosions and 
joint space narrowing at week 48 compared to baseline) was analyzed. Criterion 
validity is testing whether the criteria reflect the true clinical state, the functional 
capacity. The relative change in HAQ-score was tested for different response 
categories. Discriminant validity refers to the ability of the criteria to detect 
differences between individuals. Therefore the proportion responders in both treatment 
categories (HCQ/SASP) was compared. 
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Statistics. Missing disease activity data were filled up by interpolation when 
measurements were available within 2 weeks from the missing moment (=every 
4 weeks). X-ray progression was transformed (square-root) to "normality". The 
association between response and x-ray progression was tested with analysis of 
variance. The association between response and relative change in HAQ-score was 
analyzed with Kruskal-Wallis tests. Differences in response in both treatment groups 
was tested with t-tests or Chi-square tests (EULAR response criteria: good response=l, 
moderate response=2, no response=3, WHO-ILAR and ACR response criteria: good 
response=l, insufficient response=0). The level of significance (a) was placed at 0.05. 
Results 
Development 
The estimated Pearson correlation coefficient for remeasurements (r0) was 0.80, 
and the standard deviation (sd) of the DAS was 1.17, leading to a measurement error 
e=0.6. For good response a change from baseline exceeding 1.2 DAS-points 
(2 χ 0.6) was defined necessary. 
Figure 1. Distribution of Disease Activity Scores at moments of low (n=89) or high (n=189) disease activity 
according to treatment decisions by rheumatologists in the cohort study. The vertical lines divide the DAS 
in lom (¿2.4), moderate (>2.4 and £3.7), and high disease activity (>3.7). 
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Disease Activity Scores during moments of high and low disease activity 
according to the rheumatologists were calculated. In 142 patients 189 moments of high 
disease activity according to the rheum atologists were defined. The DAS ranged from 
1.38 to 7.15, with a mean of 4.32. Eighty-nine moments of low disease activity in 56 
patients were defined with the DAS ranging from 0.59 to 4.01, with a mean of 1.77. 
To minimize the overlap between high and low disease activity (¿5%), 2 limits were 
chosen: one at the P75 of low disease activity (DAS=2.4), and one at the P25 of high 
disease activity (DAS=3.7) (Figure 1). With these limits the DAS was divided in 3 
categories: ¿2.4 (low disease activity), >2.4 and ¿3.7 (moderate disease activity), and 
>3.7 (high disease activity). Therefore good response was defined as an improvement 
from baseline >1.2 in DAS, and a reached DAS ¿2.4. Non responders were patients 
with an improvement ¿ 0.6 (le), or patients with an improvement >0.6 and ¿1.2, and 
a reached DAS >3.7. The remaining patients were classified as moderate responders 
(Table 2). 
Table 2. EULAR response criteria based on the Disease Activity Score." 
Level 
DAS ¿2.4 
2.4< DAS ¿3.7 
DAS >3.7 
Improvement 
>1.2 
Good response p 
1 
Improvement 
sl.2 and >0.6 
Moderate response 1 
Improvement 
¿0.6 
Non response 
* Attained level of disease activity vs improvement in Disease Activity Score compared to baseline. 
Validation 
Response criteria were validated in a trial comparing sulphasalazine (SASP) 
and hydroxychloroquine (HCQ). No significant differences in patient characteristics 
were present at baseline (Table 3). 
Concurrent validity: Responders defined by WHO/ILAR [ACR] criteria were 
classified with the EULAR response criteria as: good 57% [61%], moderate 41% 
[36%], and non 2% [4%]. Non responders defined by WHO/ILAR [ACR] response 
criteria were classified with the EULAR response criteria as: good 1% [1%], moderate 
26% [27%], and non 73% [72%]. 
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Table 3. Patient characteristics at baseline (trial). 
hydroxychloroquine 
* mean (range). 
• median (range). 
sulphasalazine 
Number 
Sex (% female) 
Age* 
Disease duration (months)9 
IgM-RF (> 10 IU) (%) 
DAS* 
RAIe 
Swollen joints* 
ESRe 
General health* 
Erosions® 
Narrowing® 
30 
57% 
53.1 
8.0 
96% 
4.32 
14.0 
14.7 
39.5 
28.7 
1 
2 
(22-72) 
(3-120) 
(3.07-5.87) 
(3-34) 
(5-26) 
(5-110) 
(0-85) 
(0-18) 
(0-20) 
30 
68% 
53.5 
8.5 
91% 
4.37 
11.5 
14.4 
35.5 
39.0 
0 
0 
(22-75) 
(3-165) 
(2.48-6.77) 
(1-34) 
(5-32) 
(5-120) 
(0-100) 
(0-17) 
(0-10) 
Construct validity: the association between response assessed at several 
moments during the study and progression in joint destruction at week 48 was tested 
with analysis of variance. EULAR-response at weeks 12 (p=0.03), 20 (p=0.03), 28 
(p=0.01), 32 (p=0.00), 36 (p=0.03), 44 (p=0.04), and 48 (p=0.01) was significantly 
associated with x-ray progression: patients showing no response had significantly more 
progression in joint destruction. With WHO/ILAR and ACR response criteria no 
significant associations were found (Figure 2). 
Criterion validity: At weeks 12, 24, 36, and 48 response was compared with 
relative change in functional capacity (HAQ). Patients with good EULAR-response had 
significantly more improvement in functional capacity at all 4 periods (p=0.02, p=0.02, 
p=0.03, p=0.04 respectively). At weeks 12 (p=0.01) and 24 (p=0.01) good response 
defined by the WHO/ILAR criteria was significantly associated with functional 
capacity. With the ACR-criteria a significant association was found between response 
and disability at week 12 (p=0.02), and 48 (p=0.01) (Figure 3). 
Discriminant validity: The discriminating capacity of the response criteria was 
studied comparing the numbers of responders on sulphasalazine and on 
hydroxychloroquine. With the EULAR response criteria patients in the SASP-group 
showed a significantly better response compared to the HCQ-group at weeks 8 
(p=0.01), 16 (p=0.01), 20 (p=0.01), 28 (p=0.00), 32 (p=0.01), and 36 (p=0.00). The 
WHO/ILAR criteria only significantly discriminated between both therapies at week 
8 (p=0.01). With the ACR criteria no significant differences could be demonstrated. 
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Figure 2. X-ray progression 
over 48 weeks for categories 
of responden defined by 
EULAR (fig. 2a), WHO/ILAR 
(fig. 2b), and ACR (fig. 2c) 
response criteria at weeks 12, 
24, 36, and 48. Box indicates 
interquartile range with 
median (horizontal line). The 
total range is indicated by 
whiskers. 
1" box=good response; 
2я1 box=moderate response 
in case of EULAR, else non 
response; 
3a box=non response. 
week 12 week 24 week 36 week 48 
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Figure 3. Relative change in 
HAQ-scores for categories of 
responden defined by EULAR 
(fig. 3a), WH0/1LAR (fig. 
3b), and ACR (fig. 3c) 
response criteria at weeks 12, 
24, 36, and 48. Box indicates 
interquartile range with 
median (horizontal line). The 
total range is indicated by 
whiskers. 
1" box-good response; 
2* box=moderate response 
in case of EULAR, else non 
response; 
3a non response. 
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Discussion 
Although it has been stated that individual treatment response is an important 
outcome of interest both in clinical trials and in individual patient practice, it is seldom 
assessed.1 Only mean changes in disease activity variables within and between groups 
are tested. This is partly due to the absence of validated, commonly accepted response 
criteria. In the past several authors have made attempts to develop response measures. 
These measures, comprising a set of often arbitrarily selected variables,12'14 and 
arbitrarily defined class limits,13,14 are sometimes not even validated.14 The selection 
of components of ACR and WHCMLAR response criteria is based on consensus, 
although a large disagreement exists between described and actual judgement policies 
of disease activity by rheumatologists.15 These and other response definitions are based 
on change from baseline alone.5-612 Whether this change is significant, or relevant 
(resulting in low disease activity) is not included in the definition. Also, they assume 
a certain (20%) percentage improvement to be an equally relevant change in all 
variables.16 
The disease activity score is a composite index of disease activity based on 
rheumatologists' opinion of disease activity. Rheumatologists were unaware of the 
ESR, and therefore of the DAS, when treatment decisions were made. A multiple 
regression analysis was performed to determine the relative contribution of several 
clinical and laboratory variables in discriminating between high and low disease 
activity.3 The DAS showed good correlational, criterion, and construct validity. 
Components of the DAS (joint counts, ESR), as well as the DAS itself,17 were found 
to be sensitive to change.18,19 
The EULAR response criteria as presented here are based on change from 
baseline (measurement error) and reached level of DAS (l°w> moderate, high).4 They 
show good construct, criterion, and discriminant validity: they are associated with 
progression of joint damage, relative change in functional capacity, and discriminate 
between therapies. The median change in HAQ-score for both moderate and good 
responders was in agreement with the clinical importance difference reported by 
Redelmeier et al.20 The WHO-ILAR criteria show less association with x-ray 
progression and functional capacity, and are not sensitive to discriminate between 
SASP and HCQ (only at week 8). Disregarding the component functional capacity, the 
ACR response criteria are almost identical to the WHO/ILAR criteria. The ACR 
response criteria could only be determined at weeks 12, 24, 36, and 48, and were 
based on a smaller group of patients in whom functional capacity was measured. Due 
to the fact that physicians' global assessment was not measured in the original trial, 
67 
Chapter V 
only a global impression of the performance of the ACR criteria could be given in this 
study. They were not significantly associated with x-ray progression. An association 
with functional capacity was significant at weeks 12 and 48, however this is not 
surprising as disability is part of this response definition. The ACR criteria were not 
able to discriminate between therapies. 
We compared patient response according to EULAR criteria with response 
defined by WHO/ILAR and ACR criteria. With the latter criteria about 30% of the non 
responders, and about 40% of the responders were classified as moderate responders 
with the EULAR criteria. We studied whether the difference in results 
(construct/discriminant validity) between the 3 criteria could be explained by the 
number of categories. Therefore a two-group EULAR response (good/moderate versus 
non) was studied. The results were equal to our original three-group response, and 
better than ACR and WHO/ILAR criteria. Redefining the ACR criteria into 3 groups 
(good >50%, moderate >20%, non response £20% improvement from baseline) 
showed similar associations as found with the original 2 categories. EULAR response 
criteria based on change from baseline alone (good >1.2, moderate >0.6, non ¿0.6) had 
results comparable with ACR and WHO/ILAR criteria, and did worse than the EULAR 
response criteria including attained disease activity (data not shown). 
In agreement with the WHO/ILAR response criteria,9 the EULAR response 
criteria assume a minimum level of baseline disease activity, i.e. patients must have 
the potential to improve significantly (>1.2) to become good responders. A DAS <1.0 
indicates the absence of disease activity, therefore the baseline value of the DAS has 
to be >2.2 (1.0 + 1.2) to define response. This could also serve as an inclusion term 
for clinical trials. 
The DAS is a continuous variable developed to describe the disease process. 
EULAR response criteria give an interpretation of (change in) DAS for individual 
patients. We conclude that EULAR response criteria have construct validity, criterion 
validity, and discriminant validity. However, the performance of these criteria in 
comparison with others has to be studied further in future clinical trials comparing 
different treatment regimens. 
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Abstract 
Objective: In a prospective follow-up study of patients with early onset rheumatoid 
arthritis the prevalence of remission according to the 1981 ARA preliminary criteria 
was evaluated. 
Methods: A total number of 227 patients with a median follow-up of 3.9 years and a 
total of 2832 follow-up visits were studied. 
Results: In 9% of these visits the ARA remission criteria were fulfilled. During each 
follow-up year including 4 visits about 20% of the patients at least once were in remis-
sion. A comparison was made between the ARA remission criteria and the Disease 
Activity Score (DAS). A DAS less than 1.6 corresponded with being in remission 
according to the ARA criteria. 
Conclusion: The DAS is being proposed as a tool to define remission as it is a 
continuous validated index using variables consistent with the current views of 
assessing disease activity. 
Introduction 
Rheumatoid arthritis (RA) is a chronic systemic disease of unknown aetiology 
with as main feature polyarthritis leading to joint damage and functional impairment. 
The treatment of RA purposes a reduction of disease activity and thereby prevention 
of joint damage and functional impairment. The ultimate goal of treatment is complete 
suppression of disease activity,1,2 a state which has been defined by the preliminary 
criteria of remission of the American Rheumatism Association (ARA) in 1981.3 For 
the development of these criteria the opinion of 35 rheumatologists about the disease 
state of 344 patients (remission during treatment, remission no treatment, partial 
remission, active disease) was chosen as standard. The criteria had to be fulfilled for 
a time-period of two consecutive months, and resulted in a dichotomous scale: 
remission yes/no. In two studies these ARA criteria have been evaluated.4,5 In both 
studies the patients had an established disease, one study was done cross-sectionally5 
while in the other no standardized follow-up was defined.4 
The concept how to measure disease activity has rather changed over the last 
years. Core sets of variables have been selected which were based on consensus of 
several rheum atologists and on the validity to measure disease activity.2,6,7 It has been 
advised to assess disease activity by these, almost identical, Core sets, to gain 
uniformity in the evaluations of clinical studies. Two out of the six variables 
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mentioned in the ARA criteria of remission are not included in these Core sets, which 
limits the use of these remission criteria. 
The Disease Activity Score (DAS), which was developed for its ability to 
discriminate between high and low disease activity indicated by rheum atologists8-9 
contains variables of the above mentioned Core sets and is widely validated.10 Another 
advantage of defining remission by a continuous variable like the DAS is that 
remission can be placed on a spectrum of disease activity, which gives the opportunity 
to adjust cut-off values of DAS with respect to new insights. 
The goal of this study is both to evaluate the prevalence of remission 
according to the ARA preliminary criteria in a standardized follow-up study of patients 
with a recent onset of RA, and to investigate the relation of the ARA remission criteria 
with the Disease Activity Score. 
Patients and methods 
Patients with recent onset rheumatoid arthritis (RA) visiting the outpatient 
department of the University Hospital of Nijmegen were eligible to this study if they 
fulfilled the following criteria: RA according to the American College of Rheumatism 
criteria (ACR),11 a disease duration less than one year, and not previously been treated 
with DMARDs. Since 1985 until now 237 patients took part in this study. For different 
reasons 10 patients were not included: refused participation (n=6), or had serious 
comorbidities at the time of diagnosis which hindered follow-up (n=4, aphasia, 
malignancy, lungfibrosis). During the follow-up 15 patients died and 16 patients 
withdrew alive (refusal of follow-up (n=14), or moving far away (n=2)). 
The patients were seen by research nurses and by one of the rheum atologists 
at least every three months. The following assessments were made: morning stiffness 
(minutes), pain on a visual analogue scale of 100 mm (Pain, 0=no pain, 100=worst 
pain possible), general health on a visual analogue scale of 100 mm (GH, 0=best 
possible, 100=worst possible), erythrocyte sedimentation rate (ESR) according to 
Westergren. Also a complete joint examination took place, from which the following 
joint counts (JCs)12 were calculated: Ritchie Articular Index (RAI, 53 joints examined 
for tenderness), total number of tender joints (TOTT, 53 joints), total number of 
swollen joints (TOTS, 44 joints). 
Data concerning medication, whether patients had stopped, changed, or started 
with Disease Modifying Anti-Rheumatic Drugs (DMARDs), or Non-Steroidal Anti-
Inflammatory Drugs (NSAIDs), were also collected. Although the treatment schedule 
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of the DMARDs has slightly changed during the past years (1985-1993), the following 
sequence was used in most patients: the first step included sulphasalazine, or 
hydroxychloroquine, the second step methotrexate, or intramuscular gold, thereafter 
.D-penicillamine or azathioprine. At the start of DMARD-treatment almost all patients 
were concomitantly treated with NSAIDs, corticosteroids were allowed as adjuvans at 
all stages. 
The preliminary remission criteria of the ARA3 are described in Table 1. The 
description of the variables, however, is not sufficiently detailed. Therefore, the 
following assumptions were made in this study: the criterium no joint pain (by history) 
was replaced by the variable pain on a visual analogue scale less or equal 100 mm; 
the criterium no joint tenderness or pain on motion was fulfilled if no joint was scored 
painful out of 53 joints (total tender joints=TOTT=0); no soft tissue swelling in joints 
or tendon sheats was fulfilled if no joint was scored swollen out of 44 joints (total 
swollen joints=TOTS=0); the criteria for ESR and morning stiffness were applied as 
mentioned. Fatigue was not measured in this study, for this reason we decided that 4 
out of 5 criteria (instead of 5 out of 6) had to be present for a remission qualification 
(similar to a part in the study of Wolfe et al.).4 
For each patient the DAS8 was calculated by the following formula: 
DAS = 0.54 νΉΑΙ + 0.065 TOTS + 0.33 In ESR + 0.0072 GH 
The range of the DAS varies from 0 to 10. 
In the analyses only three monthly check-ups were included. Some patients, 
known by the rheumatologists to have low disease activity, however, refused to visit 
the outpatient department every three months. For these patients another follow-up 
schedule (a minimum of one visit a year) was applied. It was assumed that during the 
period with no check-ups the disease activity was low for it was agreed upon with the 
patients that in case complaints recurred they should call for an appointment. In the 
analyses three-monthly check-ups were added in the period in which the patient was 
included as being in remission. For all other patients, an interruption of 6 months 
(1 check-up missed) was allowed. If the interruption was longer the follow-up was 
ended at that point. 
For each patient at each check-up visit it was calculated how many ARA 
remission criteria were fulfilled. Also, the prevalence of the fulfilment of single criteria 
was computed. For each follow-up year (first to sixth) both the number of patients in 
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remission and the remission-time were computed. As measure of dispersion medians 
and interquartile ranges (P25-P75) are presented. The distribution of DAS-values for 
patients in remission and not in remission according to the ARA criteria is presented. 
Table 1. The ARA preliminary remission criteria. 
Five or more of the following criteria must be fulfilled for at least two consecutive months. 
1. duration of morning stiffness not exceeding IS minutes 
2. no fatigue 
3. no joint pain (by history) 
4. no joint tenderness or pain on motion 
5. no son tissue swelling in joints or tendon sheets 
6. erythrocyte sedimentation rate (Westergren method) less than 30 mm after 1 hour 
for a female or 20 mm after 1 hour for a male 
Results 
Of the 227 patients included in this study, 63% was female; the median age 
was 55 years (P25-P75: 43-65 years); 78% was IgM-Rheumatoid factor positive 
(>10 IU); and 53% was HLA-DR4 positive. The median number of check-ups of the 
patients was 13 (P25-P75: 5-22), and the median duration of follow-up was 3.9 years 
(P25-P75: 1.1-5.6 years). 
Table 2. The impact of a single criterium on the state of remission: % check-ups tn remission if single 
criterium is fulfilled/not fulfilled 
criterium single criterium fulfilled single criterium not fulfilled 
morning stiffness 13% 0% 
Pain 37% 1% 
tender joints 46% 0% 
swollen joints 68% 6% 
ESR 14% 1% 
Of all check-up visits of patients (n=2832) the number in which 5 and 4 of 
the remission criteria were fulfilled, were respectively: 66 check-ups (2%); and 196 
check-ups (7%). According to this at 9% of all check-up visits patients were in 
remission. 
The percentages of all check-ups (n=2832) in which a single criterium of the 
ARA-set was fulfilled was 62% for morning stiffness, 22% for Pain, 19% for tender 
joints, 6% for swollen joints and 65% for ESR. This shows that the criterium swollen 
joints is seldom fulfilled in contrast with the criterium morning stiffness and ESR. 
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Table 3. The number of patients in remission according to the ARA criteria and the remission-time per 
follow-up year. 
number of 
patients 
189 
162 
139 
112 
77 
49 
number of patients 
in remission 
21 (11%) 
31 (19%) 
35 (25%) 
27 (24%) 
20 (26%) 
10 (20%) 
median remission-time per 
follow-up year (P25-P75) 
0.27 (0.20-0.46) 
0.50 (0.23-0.76) 
0.34 (0.20-0.61) 
0.44 (0.25-0.64) 
0.50 (0.20-0.67) 
0.53 (0.27-1.00) 
In Table 2 the probability to be in remission according to the ARA is presented if a 
single criterium is fulfilled or not. The criterium swollen joints most strongly 
determined whether a patient was in remission or not. On the opposite the criteria 
morning stiffness and ESR have almost no influence on being in remission or not. 
Table 3 shows the number of patients in which at least at one time-point per follow-up 
year remission was achieved as well as the remission-time per follow-up year. Except 
for the first year of follow-up the percentages of patients in remission do not change 
over the years. The same holds true for the remission-time which does not change over 
the years. 
The distribution of DAS-values at the moment that patients fulfilled the 
remission criteria according to ARA criteria or not is shown in Figure 1. At a cut-off 
value for DAS of 1.6, the percentages of misclassification were equal for patients in 
remission and not in remission, namely 10%. In Figure 2 the course of the DAS in 
relation with the ARA criteria is presented for four patients. As can be seen in this 
figure low DAS-values correspond with being in remission according to the ARA 
criteria, and high DAS-values with not being in remission. 
Discussion 
As the ultimate goal of treatment of patients with RA is achieving a status of 
complete suppression of disease activity, a definition of remission was proposed by the 
ARA preliminary criteria in 1981.3 However only in two studies these criteria were 
evaluated.4,5 Both studies included selected patients with established disease and did 
not have a standardized follow-up. In the present study the prevalence of remission 
according to the ARA preliminary criteria in a cohort of patients which were followed 
from the start of the disease on a standardized way is described. In addition a 
comparison was made between these criteria and the DAS values as a first attempt to 
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define new remission criteria consistent with the current views of assessing disease 
activity. 
Figure 1. Comparison of DAS values with ARA preliminary remission criteria. 
% of momento 
25% 
20% 
15% 
10% 
6% 
0 1 ' " 2 3 4 5 6 7 
DAS-values 
In our study 20% of the patients fulfilled at least once per year the ARA remission 
criteria. In the study of Wolfe et al.4 out of 458 patients with an established disease 
with at least 3 clinic visits 18.1% fulfilled once the ARA criteria. The results of the 
study of Alarcon et al.,' which were based on only one check-up in two populations 
of different countries, showed prevalences of remission of respectively 1% and 30% 
of the patients according to the ARA criteria. In both last mentioned studies patients 
were selected during a visit at the clinic, this is in contrast with the present study in 
which patients were followed from the start of the disease on a standardized way. Due 
to these different selection strategies and to the methodological differences it is 
difficult to compare the remission frequencies of the different studies. 
We had to deal with several problems when applying the ARA remission 
criteria in our study. In the first place the criteria are not sufficiently described. Due 
to this, several assumptions had to be made to use these criteria, also in this study, 
which will have consequences for the found prevalence of remission. For example, the 
criteria no joint pain and no joint swelling were measured by JCs including 
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Figure 2. The course of the original DAS and the preliminary criteria in some individual patients. 
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respectively 53 joints and 44 joints. If JCs measuring more joints are included in the 
criteria, a lower prevalence could be expected. Secondly in the definition of remission 
according to the ARA also a time-period is included. This aspect, however, could not 
be investigated in the original study3 and in the studies of Wolfe et al.4 and Alarcon 
et al.5 for their follow-up was not standardized. As the frequency of follow-up in our 
study, once in three months, did not deviate much from the frequency included in the 
definition we were able to overcome this problem. Finally in our study the variable 
fatigue was not included, therefore it was stated that 4 out of 5 criteria should be 
fulfilled. It can be assumed that fatigue is the less discriminating variable for 
remission, because it is the least disease-specific variable of the criteria, it is difficult 
to assess, and it is expected to be correlated with morning stiffness. In the original 
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study it is stated that the sensitivity and specificity of accepting 4 criteria fulfilled out 
of 6 criteria are respectively 90% and 84% and of 5 out of 6 criteria respectively 72% 
and 96%. By excluding the single variable fatigue (4 fulfilled out of 5 criteria) the 
specificity and sensitivity will be somewhere in between. Due to this we expect that 
the prevalence of remission according to the criteria will be higher in this study than 
in studies evaluating 5 out of 6 criteria. 
In the original study of the ARA criteria3 the variable morning stiffness 
discriminated best. Recently the variable morning stiffness has been evaluated by 
Hazes et al.13 It appeared that this variable was a poor discriminator between RA and 
non-inflammatory joint disease, and between active and inactive RA. In the present 
study this was confirmed for the influence of this variable on remission could be 
neglected: many patients fulfilling this criterium were not in remission. In contrast with 
the variable swollen joints which had the largest influence: if it was fulfilled there was 
a great chance that the patient was in remission according to the ARA criteria. 
The assessment of disease activity in rheumatoid arthritis has undergone quite 
a change since the proposal of the ARA preliminary remission criteria in 1981. At this 
moment several variables included in the ARA remission criteria are judged to be less 
valid and were therefore not included in the ACR and EULAR Core set.2,5,6 The 
Disease Activity Score (DAS) is an extensively validated composite index which can 
be calculated with 3 or 4 variables from the Core
 sets.
7
·
8
·
12
·
14
·
15
·
16
 Including more 
variables in the DAS did not increase its validity.11 The DAS, which has a continuous 
scale, corresponds strongly with the ARA preliminary remission criteria. This is not 
surprising as the most important elements of the ARA criteria (swollen joints, tender 
joints, Table 2) are included in the DAS. At a cut-off value of 1.6 the percentages of 
misclassification for patients' check-ups in remission or not in remission was 10%. The 
problem with a dichotomous variable however is that a small change in disease activity 
may have a great impact whether a patient fulfils the remission criteria or not. As can 
be seen in Figure 2 during a "remission-period" (most of the check-ups in a certain 
time period fulfilling the criteria) at one time-point a patient does not completely meet 
the criteria, e.g. the follow-up of patient 1 and 4 in Figure 2. 
This study of patients with recent onset RA shows that remission according to 
the ARA criteria occurs seldom, 9% of all check-ups in patients with a median follow-
up of 3.9 years were in remission. During each follow-up year wherein the patients 
were assessed 4 times, about 20% of the patients fulfilled once the ARA remission 
criteria. The duration of the remission was about 0.40 year. We have shown that the 
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ARA criteria can be replaced by the DAS criteria for remission. The DAS would be 
preferable because it is a continuous validated index using Core set variables. If 
remission should be a dichotomous outcome, this study suggests a cut-off point of the 
DAS of 1.6. For comparison a patient without any swollen or tender joints and an ESR 
of 10 mm in 1 hour has a DAS of 1.0. Further validation of these provisional DAS 
remission criteria are needed. It has to be investigated for instance whether patients in 
remission do not have radiographic progression or functional loss in this period. 
Besides the importance of the duration of remission should be further elaborated. 
Acknowledgements: We would like to thank B. Dijkmans and S. ten Wolde for fruitful discussions during 
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Abstract 
Objectives: In a prospective study started in 1985, the mortality of an incident-cohort 
of patients with recent onset rheumatoid arthritis (RA) was analyzed. 
Patients and methods: O f a study-group of 240 patients the observed mortality was 
analyzed in relation with the expected mortality, calculated with the aid of life-tables 
of the general population of the Netherlands (sex- and age matched). The prognostic 
value of several variables was analyzed. 
Results: Of the study-group 17 patients died. The death causes could be divided into 
cardiovascular and respiratory cause (n=9), cancer (n=4), sepsis (n=l), renal 
insufficiency of unknown cause (n=l), perforation of the oesophagus probably related 
to the treatment with Non-Steroidal Anti-Inflammatory Drugs (n=I), and pancytopenia 
during aurothioglucose treatment (n=l). 
Conclusions: The observed mortality did not deviate from the expected mortality. Only 
age at start was a significant predictive variable. 
Introduction 
Rheumatoid arthritis (RA) is a chronic disease which is long known to cause 
severe disability. According to several studies1,2A4,S RA has also a higher mortality-rate 
than the general population. However, all these studies have been criticized for their 
definitions of RA, selection of patients (hospital-based, trial-patients, community-
based), choices of controls (general population, patients with other diseases etc.), 
lengths of follow-up, durations of RA prior to the study (incident cases versus 
prevalent), methods of statistical analyses, and the causes of death ascribed to RA.6 
Inferences of these studies to patients with RA in general are therefore not valid. Next 
to this, in all studies the patient's onset of RA was before 1980. Since 1980 there has 
been a radical change in the treatment of RA. In this period, the two presently most 
commonly used Disease Modifying Anti-Rheumatic Drugs (DMARDs) were introduced 
in the treatment of RA (sulphasalazine, methotrexate). Also the number of NSAIDs 
(Non-Steroidal Anti-Inflammatory Drugs) available in the treatment of RA has 
increased. Finally, DMARDs are given earlier in the disease course, sometimes even 
in combinations. Since all these drugs do have potentially lethal complications, these 
changes in the therapeutic strategies could lead to either a better or a worse life 
expectancy (LE). 
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Prognostic factors of mortality have also been investigated in studies including 
patients with onset of RA before 1980. In the studies of Pincus et al.,7,8 in which 
patients were included with a mean disease duration at start of 11.2 years, the 
following variables appeared to be predictive: age, joint count, formal educational 
level, a questionnaire of activities of daily living, oral corticosteroid use. Rasker et al.9 
who investigated a study-group of patients with recent onset RA, found that age, 
functional class according to Steinbrocker, and ARA grading one year after disease 
onset was different between survivors and deaths. Other factors as the Arthritis Impact 
Measurement Scale, the Health Assessment Questionnaire, and disease duration were 
found to be predictive in several other studies.10*11 
The goal of this study is to investigate mortality and its prognostic factors in 
an incident-cohort of patients with recent onset RA followed-up since 1985. 
Patients and methods 
Mortality 
Patients with a recent onset RA referred to the outpatient department of the 
University Hospital of Nijmegen during 1985-1993 were eligible for this study if they 
fulfilled the following criteria: RA according to the American Rheumatism Association 
criteria (ARA, 1987), and a disease duration less than one year. A total of 240 patients 
with a recent onset of RA were referred, and were included in the analyses of 
mortality. The health status of all these patients was checked till October 1993. During 
this period 17 patients died, cause and date of death were obtained from the 
rheum ato logists or from the general practitioner. 
The mortality of this RA-population (Kaplan Meyer survival function) was 
compared with the expected mortality based on the general population of the 
Netherlands in 1987 matched for age and sex.12 
Prognostic factors 
To be able to evaluate prognostic factors, patients with recent onset RA 
(incident-cohort) should not have been treated previously with DMARDs and should 
have sufficient follow-up time in which data concerning the course of the disease are 
gathered. Therefore all patients fulfilling the criteria above (n=240), not previously 
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treated with DMARDs, not having serious comorbidities, who would participate in a 
follow-up study were included in the analyses of prognostic factors. Excluded for 
different reasons were 36 patients: not reported before the start of a DMARD (n=26), 
refused participation (n=6), or had serious comorbidities at the time of diagnosis 
(n=4, aphasia, malignancy, lungfibrosis). Of the total of 240 patients with recent onset, 
204 patients participated in the follow-up study. Of this group 15 patients died. 
All patients were followed in a standardized way. Every three months patients 
were seen by specially trained research nurses and by rheumatologists. The following 
assessments were made every three months: pain (on a visual analogue scale of 100 
mm, 0=no pain, 100= worst pain possible), general health on a visual analogue scale 
(0=best possible, 100=worst possible), grip strength with a vigorimeter (mm Hg), the 
number of tender joints (n=53), the number of swollen joints (n=44), the Ritchie 
Articular Index (RAI).13 Every three months the research nurses recorded whether a 
patient had stopped, changed or started with a drug (DMARD, NSAID). The 
educational level of the patients was also recorded and was divided into 5 categories.14 
Laboratory assessments included ESR according to Westergren (mm in 1 hour), IgM 
rheumatoid factor (normal ilO IU/ml), and sera were typed for HLA-DR4. Every six 
months the patient completed a Health Assessment Questionnaire (HAQ).13 
Prognostic factors for mortality were analyzed by Cox proportional hazards 
model, multivariate with age (start of RA) and gender fixed in the model. The 
variables educational level, IgM rheumatoid factor, HLA-DR4, were analyzed by their 
value at entry. The number of tender joints, number of swollen joints, Disease Activity 
Score (DAS) based on three variables,16 and HAQ were analyzed in three different 
ways: 1. the value at entry; 2. the value after one year participation in the study; and 
3. the mean value of all check-ups of the first year of participation. If the necessary 
follow-up period was not reached, the mean of the available period was calculated. 
Next to these variables, the use of DMARDs and corticosteroids during the first year 
of follow-up were analyzed for their prognostic value. For power-reasons, the number 
of variables included in the regression model was kept low. 
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Results 
Mortality 
Survival functions (Kaplan Meyer) of the patients with RA versus the general 
population of the Netherlands of 1987, sex and age matched are presented in 
Figure 1. 95% Confidence intervals are shown for the study-population. The mortality-
rate of the RA patients did not deviate from that of the general population of the 
Netherlands. 
The death causes ascribed by the rheumatologists or general practitioners could 
be divided into cardiovascular and respiratory cause (n=9), cancer (n=4), sepsis (n=l), 
renal insufficiency of unknown cause (n=l), perforation of the oesophagus, probably 
related to NSAID treatment (n=l), and pancytopenia during aurothioglucose treatment 
(n=l). 
Figure 1 Survival functions (Kaplan Meyer) of patients -with recent onset of RA (study-population) versus 
the general population of the Netherlands 1987, sex and age matched Confidence intervals (95%) of the 
study-population are shown. 
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Prognostic factors 
The characteristics and median values of all check-ups of the first year of 
follow-up of the clinical variables are presented in Table 1. It appeared as if the group 
deaths had worse clinical scores. To test the prognostic value of these clinical scores 
they were evaluated multivariately by Cox proportional hazard model, with age (at 
start) and gender fixed in the model. In the model in which only age and gender were 
included, age at start was a significant prognostic factor (p=0.0001). Gender, however, 
was not a significant predictive factor (p=0.19). Educational level, IgM-Rf, HLA-DR4, 
4 clinical scores, and the use of DMARDs and corticosteroids during the first year of 
follow-up were analyzed. All these variables were not significantly predictive. Some 
of the results are presented in Table 2. 
Table 1. The characteristics of the study population." 
female (%) 
age at start (yr)' 
education level (%) 
very low 
low 
moderate 
high 
very high 
IgM-Rf+ (>10 IU) 
HLA-DR4+ 
HACf 
RAI® 
number of tender joints9 
number of swollen joints3 
DASe 
survivors n= 189 
64% 
54(14) 
37% 
30% 
14% 
8% 
11% 
77% 
54% 
0.36 (0-1.98) 
7.3 (0-30.8) 
9.0 (0-33.9) 
13.1 (0-32.7) 
3.46 (1.2-5.8) 
deaths n=15 
47% 
71(7) 
73% 
0% 
27% 
0% 
0% 
80% 
42% 
0.67 (0-1.33) 
11.0(3.9-29) 
12.8 (4.7-30) 
13.3 (3.5-27.1) 
4.02 (2.7-5.2) 
* HAQ=Health Assessment Questionnaire, DAS=Disease Activity Score. 
Mean (sd). 
• Median (range). 
The drag use, DMARDs and corticosteroid, of the deaths and survivors during 
the follow-up is shown in Table 3. The use during the complete follow-up, however, 
cannot easily be compared between the two groups, since the probability to receive 
drugs is proportional to the survival time. Therefore we analyzed the drug use during 
the first year of follow-up. This drag use was tested in a Cox proportional hazards 
model. It was not significantly predictive (p=0.99). The prognostic value of the use of 
corticosteroids during the first year was also tested, it was not significant (p=0.79). 
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Table 2. Multivariate evaluation of the prognostic value of variables by Cox proportional hazards model 
(age and gender fixed). 
variables (levels) Risk Ratio (conditional) p-value 
educational level (5) (high versus low education) 0.73 0.31 
IgM-Rf(2) 0.83 0.79 
HLA-DR4 (2) 0.89 0.85 
number of tender joints β 1.04 0.16 
number of swollen joints β 0.98 0.73 
D A S β 1.78 0.07 
HAQ* U 8 0.79 
® mean value of all check-ups of the first year of follow-up. 
Table 3. Drug use during the follow-up. 
during the complete follow-up during the first year 
survivors deaths survivors deaths 
DMARD 
hydroxychloroquine 
sulphasalazine 
aurothioglucose 
methotrexate 
azathioprine 
D-penicillamine 
corticosteroid 
93% 
33% 
84% 
38% 
37% 
10% 
5% 
30% 
100% 
53% 
73% 
53% 
27% 
7% 
0% 
67% 
90% 
28% 
56% 
5% 
17% 
100% 
47% 
47% 
6% 
20% 
Discussion 
In this prospective study the mortality of an incident-cohort of patients with 
RA, developing RA after 1985, was analyzed. Seventeen patients of a study-group of 
240 patients died. The observed mortality of this study-group was comparable with the 
expected mortality calculated with the aid of life-tables of the general population of 
the Netherlands (sex- and age matched). The death causes in this study were 
comparable with results of other studies.17 Two death causes could be related directly 
to the treatment of RA. 
The similar mortality of the study-group and the general population is in 
contrast with the results of other studies performed before 1985. This could suggest 
that life expectancy (LE) of patients with RA since 1985 has increased. However, all 
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1 
2 
3 
4 
5 
6 
7 
98.0% 
96.0% 
96.0% 
96.0% 
94.0% 
90.4% 
87.8% 
Table 4. Percentages survival of the study-population ofRasker et al.' incident-cohort of 1957-1963, versus 
this study, incident-cohort after 1985. Confidence intervals (95%) are given of the survival percentages of 
this study. 
years of Rasker et al. 95 % CI of the percentages of 
follow-up n=100 the study-population (n=240) 
97.3% - 100% 
96.0% - 99.8% 
96.0% - 99.8% 
94.4% - 99.2% 
87.0% - 96.0% 
84.5% - 94.9% 
83.3% - 94.6% 
these other studies have been criticized for several aspects, as mentioned in the 
introduction. Of all studies there is only one study in which also an incident-cohort of 
patients with RA (before 1980) was included. This study by Rasker et al.9 included 
100 patients, who were seen between 1957 and 1963 in several clinics for Rheumatic 
Diseases in Great-Britain. This study did not compare their results with their general 
population. They, however, showed survival curves of two classes of their group of 
patients: 1. ARA classification one year after disease onset graded as definite 
(n=48 patients) 2. classical RA (n=52 patients). The survival curve of the whole group 
of patients (n=100) could be drawn by weighting the percentages survival per year 
follow-up by the number of patients in the two groups. Table 4 shows the results as 
compared to the 95% CI of the survival percentages resulting from our study. When 
comparing the survival percentages between the two studies no significant difference 
was found. 
However, to be able to compare the results of these 2 studies the influences 
of the different sex and age distributions, of the different countries with perhaps 
different mortalities, and of the trend of the mortality over the years had to be 
checked. The sex and age distributions between the two studies are almost similar. In 
our study 63% was female versus 64% in the study of Rasker et al. The mean age in 
our study was 54 years at onset, ranging between 17 to 86 years, versus 51 years with 
a range of 18-81 in the study of Rasker et al. The influence of the different countries 
and the trend of the mortality over the years was checked by comparing the survival 
curves of 1962 and of 1987 for both the Netherlands and England & Wales. It 
appeared that the life expectancy (LE) of the general population of the Netherlands 
was slightly higher than the LE of England & Wales. Next to this, the LE of 1987 was 
slightly higher than the LE of 1962, for both countries. Therefore the conclusion 
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that the survival percentages between the two studies are similar cannot be influenced 
or explained by these changes of the LE. 
In the follow-up study, in which 204 patients were included, several variables 
were analyzed for their prognostic value. Although Table 1 shows that deaths appear 
to have worse clinical scores, only age at start appeared to be a significant predictive 
variable. Other studies found that clinical scores as well as educational level were 
significant predictive factors.7·8,10,11 These different results could be due to several 
reasons. Studies which evaluate mortality and prognostic factors can be criticized as 
mentioned earlier. The main difference between most studies and our study is the 
selection of patients, incident cohorts versus prevalent cohorts. The selection of 
prevalent cases could lead to selection bias. For example, patients with a longer 
disease duration visiting an outpatient department/ or clinic, will probably be a 
selection of patients with more severe disease activity. Next to this selection-bias, 
several variables are difficult to compare between different studies/countries, for 
example different strategies of drug treatment (corticosteroid use), and formal 
educational level. For example, in the study of Pincus et al. prognostic variables were 
evaluated by Cox proportional hazards model (stepwise),8 this resulted in 3 prognostic 
variables, formal educational level, corticosteroid use, and activities of daily living 
(p-value<0.05). In this study corticosteroid use during the complete follow-up entered 
in the model. The prevalence of corticosteroid use during the complete follow-up, 
however, differ between that and our study, more patients (76.7%) using 
corticosteroids in the study of Pincus et al. than in our study (32.8%). In our cohort 
corticosteroid use during the first year of follow-up was not a prognostic factor. Other 
results could also be due to the changed therapeutic strategies in patients diagnosed 
after 1980, this could disturb the relation of variables with mortality. In our study 
functional capacity according to the HAQ was not a significant prognostic factor. The 
functional capacity according to the HAQ improved during the first 5 years compared 
to the value at start. After 5 years the functional capacity is still better than at start. 
This is shown in Table 5. In a study of Rasker et al.18 the functional capacity of the 
survivors worsened during the follow-up. This was confirmed in a study in which 
patients were included with a mean disease duration of 10 years (sd 6 years), first seen 
between 1966 and 1974, the disability (HAQ scores) was found to develop most 
rapidly during the first years after disease onset and a slow, nearly linear rate of 
increase after 10 years was assumed.19 
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Table 5. The course of the Junctional capacity (HAQ scores) during the years offollow-up. 
years of follow-up at 1 2 3 4 S 
entry 
HAQ 
mean score 
mean difference of the patients 
compared to baseline 
-SEM 
- η 
0.65 
0 
173 
0.41 
-0.24 
0.04 
170 
0.46 
•0.18 
0.04 
162 
0.48 
-0.14 
0.04 
144 
0.53 
-0.06 
0.05 
124 
0.59 
0.01 
0.06 
75 
0.54 
0.06 
0.07 
52 
From this study we concluded that the mortality of the population with RA 
does not differ from the general population. Further research, however, in patients with 
a longer follow-up is necessary for it has been suggested that the mortality of RA-
patients versus the general population increases with increasing duration of the 
disease.20 Besides the mortality in this incident-cohort of patients with recent onset of 
RA after 1983 was comparable with the mortality seen in a study, including patients 
with recent onset of RA in 1957-1963. Only age at start was a prognostic factor for 
mortality. 
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SUMMARY AND CONCLUSIONS 
Chapter Ш 
Summary and conclusions 
Rheumatoid arthritis is a chronic systemic disease of unknown etiology. The 
most common feature is symmetric poly-arthritis, which, even early in the disease, 
leads to functional disability and to damage of joints. Due to the heterogeneous 
presentation of RA, many variables are used in the evaluation of the clinical course of 
the disease. The validity of these variables to measure disease activity was tested in 
many studies, worldwide. Based on the results of these studies the most valid variables 
were selected, forming the Core set variables. In these Core sets the following aspects 
are represented: joint involvement, pain, functionality, laboratory evaluation of one 
acute-phase reactant, the physicians' and patients' opinion on disease activity, and 
radiographic damage. The Core sets form a minimal set of variables which should 
always be included in clinical studies. If a specific aspect of the disease is investigated, 
or if a patient has a specific complaint, variables related to the specific aspect or 
complaint should be taken into account in addition to the Core set variables. Even with 
the development of the core set variables, some problems in the clinical evaluation of 
RA remain, some of these are investigated in this thesis. 
In all studies of this thesis data from patients participating in a longitudinal 
prospective follow-up study of the University Hospitals of Nijmegen and Groningen 
were used. This follow-up study started in 1985, and until now, all consecutive patients 
attending these hospitals with a disease duration less than one year are included. Due 
to this the number of patients mentioned in the different chapters vary. The frequencies 
of visits (at least once in three months), and assessments were determined in a 
standardized follow-up scheme. In rheumatology-research this is a unique incident-
cohort with a standardized long follow-up, in which patients regularly (more than once 
a year) visit an outpatient department of rheumatology. One of the main advantages 
of this is that in contrast with studies with no standardized follow-up, even patients 
who develop a mild disease remain participants. 
The measurement of joint involvement, as the symmetric poly-arthritis is 
prerequisite for RA, is important. To be able to measure this, several joint counts (JCs) 
were developed in which different abnormalities and different number of joints were 
included. In JCs known from literature, some of the abnormalities are warmth, 
limitation of motion, tenderness, swelling and deformity, and the numbers of joints 
included range from 28 to 86. The abnormalities can be graded for their severity, and 
the joints can be weighted for their surface areas. In the Core set variables JCs 
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measuring only tenderness and swelling were selected. The ACR Core set of variables 
specifies that the tender JC has to measure a total of 68 joints, and the swollen JC a 
total of 66 joints. The EULAR Core set specifies a total number of tender joints 
including 53 joints, and a total number of swollen joints of 44 joints. In Chapter 1 the 
reliability and the validity of 37 JCs to measure disease activity was evaluated by 
considering three different abnormalities, tenderness, swelling, and the combination of 
tenderness and swelling, and by grading for tenderness and / or weighting for surface 
area of the joints. It was concluded that the validity and reliability of JCs measuring 
28 joints were similar to JCs including more joints. With respect to grading of 
tenderness, it was concluded that graded JCs were almost always more valid than 
ungraded JCs. Weighted JCs were almost always less valid and reliable than 
unweighted JCs. Taking simplicity into account the 28 JC, not graded and not 
weighted was preferable. On behalf of this study and some comparable studies, the 
ACR and the EULAR advised 28 JCs in their Core sets, recently. 
In the assessment of RA the role of self-administered forms filled in by 
patients has gained ground during the years. Also the self-administration of joint 
involvement has already been investigated, however a comparison between several of 
these JCs has never been performed. In Chapter 2 the reproducibility and the validity 
to measure disease activity of several self-administered JCs has been evaluated. It 
could be concluded that the joint involvement measured by patients was reproducible, 
however, the correlation with the joint examination of the assessors was moderate. The 
relation of the self-administered scores and the assessors' scores with other disease 
activity variables were comparable. Therefore at the present time the assessors' joint 
examination cannot be replaced by self-administered joint involvement. The value of 
the self-administered joint involvement in the evaluation of disease activity should be 
investigated in the future. 
Because disease activity cannot be measured by one variable several indices, 
in which several aspects of the disease are combined (by weighting, by summation), 
were developed. With these indices the course of RA in groups and in individual 
patients can be compared. Several of these indices include variables which are less 
valid (not included in Core sets), therefore the use of these indices will be hampered 
in the future. One of the indices which can be computed by core set variables is the 
Disease Activity Score (DAS), which has been developed by our group in patients with 
recent onset RA. In Chapter 3 this index was adjusted to the results from Chapters 1 
and 2, and next to this its composition was investigated in patients with a longer 
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disease duration. It could be concluded that there was no influence of disease duration 
on the composition of DAS. The comprehensive JCs, Ritchie Articular Index and total 
number of swollen joints which are included in the DAS were replaced by 28 JCs. The 
validity to measure disease activity and the discrimination between high and low 
disease activity (as indicated by clinical decisions of rheum atologists) were comparable 
between the Modified Disease Activity Scores including 28 JCs and the DAS including 
comprehensive JCs. 
The DAS is an effective measure that can discriminate between active drug 
and placebo treated patient groups, as has been shown in a study from Fuchs et al. 
There is, however, increasingly awareness for the assessment of individual response 
(the number of responders in the groups). Response is a disease specific outcome 
which can be measured by DAS. The response includes two aspects namely a relevant 
change in disease activity, and a reached level of the DAS. In Chapter 4 response-
criteria were defined and validated. A good response was defined as a decrease of 
DAS of more than 1.2 (DASpoints), and an end-value which should be lower than 2.4 
(DASpoints). It could be concluded that DAS response criteria have construct validity 
(predict radiographic damage), criterion validity (relate to disability) and discriminant 
validity (sensitive to change). 
The ultimate goal of treatment is complete suppression of disease activity, 
which could be called remission. Remission has been defined by preliminary criteria 
of the ARA. These criteria were built out of variables which, however, are not 
included in Core set variables. Therefore a comparison of DAS-values with these 
criteria is presented in Chapter 5. Next to this the prevalence of remission in an 
incident-cohort was calculated. It could be concluded that during a median follow-up 
of 3.9 years (median number of assessments is 13) 29% of the patients fulfilled at least 
once the ARA criteria of remission. The number of patients in remission and the 
duration of remission is almost constant over the years. It could also be concluded that 
the ARA criteria which are difficult to assess could be replaced by DAS. The use of 
DAS would be preferable because next to the inclusion of Core set variables, the DAS 
represents the complete spectrum of disease activity, and the DAS correlates with 
radiographic damage. 
The most definite outcome variable is mortality. In Chapter 6 mortality of an 
incident-cohort of patients with recent onset of RA after 1985 was compared with the 
mortality of a cohort with onset during 1957-1963. The prognostic values of the 
98 
Summary and conclusions 
Disease Activity Score and other variables for mortality were also investigated. It 
could be concluded that the mortality of patients in the first 6 years did not differ from 
the general population. Besides this the mortality in this incident-cohort of patients 
with recent onset after 1985 was comparable with the mortality seen in the study 
including patients with recent onset in 1957-1963. Only age at start was a prognostic 
factor for mortality. 
Although we hope that the different studies in this thesis have solved some of 
problems in the assessment of RA, further research should take place for i.e. the 
sensitivity to change of 28 JCs, Disease Activity Scores, and Modified Disease 
Activity Scores; the value of the self-administered JCs in the assessment of the clinical 
course of RA; the mortality in an incident-cohort of patients with a long disease 
duration. With the development of the Core set variables, the "what to assess?" 
question is mainly solved. However, by solving only the question "What to assess?" 
the comparability of study-results is not guaranteed. A standardisation of the 
measurements and of the follow-up, the questions "how to assess the variables?", and 
"when or how often to assess these variables?", should take place in the future. 
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Reumatoïde artritis (RA) is een chronische ziekte, die zich kenmerkt door 
ontstekingen van de gewrichten. Deze ontsteking geeft aanleiding tot klachten zoals 
pijn, stijfheid en functionele beperkingen en zij veroorzaakt op den duur schade aan 
de gewrichten. Buiten de gewrichten kunnen ook de organen, huid, longen, milt etc. 
aangedaan zijn. De behandeling van RA is vooral medicamenteus. De geneesmiddelen 
worden momenteel onderverdeeld in twee categorieën: 1. symptomatisch effectieve 
geneesmiddelen ("Symptom Modifying Anti-Rheumatic Drugs": SM-ARDs), waaronder 
"Non-Steroidal Anti-Inflammatory Drugs" (NSAIDs), corticosteroïden en de meeste 
huidige "Slow Acting Anti-Rheumatic Drugs" (SAARDs). 2. Middelen die het beloop 
van de ziekte beïnvloeden ("Disease Controlling Anti-Rheumatic Treatment": DC-
ARTs). De afgelopen jaren heeft de medicamenteuze behandeling van RA grote 
veranderingen ondergaan. Dit komt o.a. door een toename in het aantal beschikbare 
SAARDs voor RA en daarnaast is de behandelingsstrategie gewijzigd. Door het groter 
aantal beschikbare SAARDs en door een veranderde visie op behandeling wordt sinds 
ca. 1980 zo vroeg mogelijk na de diagnose RA gestart met de behandeling van 
SAARDs om het beloop van de ziekte te kunnen beïnvloeden. Vóór 1980 werden deze 
patiënten voornamelijk behandeld met NSAIDs. 
Voor de klinische patiëntenzorg is het evalueren van de invloed van de 
behandeling (bijwerkingen, effect e.d ) als ook van het beloop van de ziekte van groot 
belang. Het beloop van de ziekte wordt door de heterogene presentatie van de ziekte, 
zowel wat betreft het wel of niet optreden van symptomen in de tijd, als door het grote 
aantal verschillende symptomen, gemeten door veel variabelen. Verschillende 
onderverdelingen kunnen worden gemaakt van deze variabelen. Een onderverdeling is 
in laboratorium-, röntgenologische, klinische, functionele en algehele gezond-
heidsmetingen. Een andere onderverdeling is in proces- en uitkomstvariabelen. 
Procesvariabelen representeren de situatie van de ziekte op een specifiek moment. 
Uitkomstvariabelen zijn variabelen waarin het gezondheidsverlies ten gevolge van de 
procesvariabelen wordt gemeten, de situatie weergeven over de tijd, dit is een 
cumulatieve maat. De uitkomstvariabelen kunnen onderverdeeld worden in ziekte-
specifieke (bijv röntgenafwijkingen) en niet-ziekte-specifieke variabelen (bijv. 
invaliditeit, kosten, sterfte). 
Het grote aantal variabelen waarmee de ziekte in onderzoek geëvalueerd wordt, 
heeft geleid tot problemen. Enkele problemen zijn: 1. resultaten van studies waarin 
102 
Samenvatting 
verschillende variabelen gebruikt worden kunnen niet onderling vergeleken worden. 
2. de kans op het vinden van een statistisch significant therapeutisch effect wordt 
groter als een groot aantal variabelen getest wordt (bij geen correctie). 3. daar 
onderzoekers beslissen welke variabelen gepresenteerd worden in een publikatie, is het 
mogelijk dat alleen die variabelen gepresenteerd worden die leiden tot een gewenst 
resultaat. Naast het grote aantal variabelen, is er weinig bekend over de validiteit van 
deze variabelen om ziekte-activiteit te kunnen meten. Hierdoor blijven er studies 
bestaan waarin variabelen zijn opgenomen die ongevoelig zijn om een reeds bewezen 
therapeutisch effect aan te tonen. Door dit laatste probleem zijn de afgelopen jaren veel 
studies opgezet die de validiteit van variabelen hebben onderzocht. De resultaten van 
deze studies hebben geleid tot de ontwikkeling (internationaal) van een kemset van 
variabelen waarmee ziekte-activiteit gemeten dient te worden. Met deze ontwikkeling 
worden enkele van de bovengenoemde problemen opgelost. In de kemset zijn de 
volgende variabelen opgenomen: gewrichtsscores waarin pijnlijke en gezwollen 
gewrichten gemeten worden, pijn aangegeven door de patiënt, ziekte-activiteit 
aangegeven door arts en patiënt en een laboratoriumvariabele (BSE, CRP). Naast deze 
variabelen wordt bovendien een röntgenscore geadviseerd. 
Ondanks deze belangrijke ontwikkeling van de kemset bleven er problemen 
bestaan. In dit proefschrift zijn er enkele aan bod gekomen. 
Voor de studies die vermeld zijn in dit proefschrift is er gebruik gemaakt van 
gegevens van patiënten die meededen aan een longitudinaal prospectief onderzoek van 
de Academische Ziekenhuizen Nijmegen en Groningen. Het prospectieve onderzoek 
startte in 1985 en sindsdien zijn alle patiënten er in opgenomen waarbij recentelijk de 
diagnose RA gesteld werd. Deze patiënten werden verzocht om elke drie maanden de 
poliklinieken te bezoeken. Gedurende deze visites werden op een gestandaardiseerde 
wijze meerdere variabelen gemeten. 
Een van de problemen betreft het gebruik van gewrichtsscores. In de literatuur 
wordt een groot aantal verschillende gewrichtsscores gepresenteerd. Zij kunnen 
verschillen doordat ze meerdere afwijkingen kunnen meten: pijn, zwelling, warmte, 
bewegingsbeperking, deformiteiten en alle mogelijke combinaties tussen deze. Deze 
afwijkingen kunnen bovendien in de gewrichtsscore gegradeerd worden naar ernst, of 
gewogen worden naar grootte van de gewrichtsoppervlakte. Daarnaast verschillen de 
gewrichtsscores met betrekking tot het aantal gewrichten: variërend tussen 28 en 86. 
De kemset beschrijft gewrichtsscores waarin twee afwijkingen gemeten worden: pijn 
en zwelling. Ondanks deze beperking blijft het aantal mogelijke gewrichtsscores nog 
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steeds groot en zullen bovengenoemde problemen nog steeds optreden. In Hoofdstuk 
2 van dit proefschrift worden de verschillende gewrichtsscores die pijnlijke en/of 
gezwollen gewrichten meten, geëvalueerd naar hun validiteit en hun betrouwbaarheid 
om ziekte-activiteit te kunnen meten. Geconcludeerd werd dat een gewrichtsscore die 
bestaat uit 28 gewrichten, vergelijkbaar was met gewrichtsscores bestaande uit meer 
gewrichten. Het graderen van de pijn binnen een gewrichtsscore bleek tot meer valide 
gewrichtsscores te leiden dan bij gewrichtsscores waarin de pijn niet gegradeerd werd. 
Het tegendeel gold voor de gewrichtsscores waarin de pijn en/of zwelling gewogen 
werden naar gewrichtsoppervlakte. Rekening houdend met eenvoud en snelheid van 
uitvoeren, werden die gewrichtsscores aanbevolen die bestaan uit 28 gewrichten waarin 
de pijn en of zwelling niet gegradeerd en niet gewogen werden. Onlangs zijn deze 
gewrichtsscores opgenomen in de kernset variabelen. 
Daar de laatste jaren het gebruik van patiënten-vragenlijsten in de kliniek 
toeneemt, wordt in Hoofdstuk 3 de mogelijkheid onderzocht om de door ver-
pleegkundigen of artsen gemeten gewrichtsscore te vervangen door een gewrichtsscore 
die berekend is uit vragentijstgegevens waarin de patiënt heeft aangegeven of hij/zij 
pijnlijke en/of gezwollen gewrichten heeft. De reproduceerbaarheid van de resultaten 
van de vragenlijst bleek goed te zijn: de patiënt gaf vergelijkbare informatie bij het 
twee keer kort na elkaar invullen van de vragenlijst. De overeenkomst tussen de 
patiënten-gewrichtsscores en de gewrichtsscores van de artsen/verpleegkundigen echter 
was slecht. Omdat deze overeenkomst slecht was, is de relatie van de patiënt-
gewrichtsscores met andere zdekte-activiteitsmaten gemeten. Die betrekking bleek 
vergelijkbaar te zijn met de relatie tussen deze maten en gewrichtsscores van de 
artsen/verpleegkundigen. Dit leidde tot de conclusie dat op dit moment de 
gewrichtsscores van de artsen/verpleegkundigen niet vervangen kunnen worden door 
patiënt-gewrichtsscores. Verder onderzoek is nodig naar de waarde van deze patiënt-
gewrichtsscores in de kliniek. 
Door de ontwikkeling van de kemset variabelen worden enige van 
bovengenoemde problemen opgelost. Enkele problemen blijven echter bestaan, bijv het 
probleem van tegenstrijdige resultaten. De ontwikkeling van een ziekte-activiteits-index 
waarin meerdere variabelen gecombineerd worden, is een oplossing hiervoor. In het 
verleden zijn er reeds indices ontwikkeld. Velen hiervan bestaan echter uit variabelen 
die niet opgenomen zijn in de kemset van variabelen, waardoor ze in de toekomst 
minder valide worden. Recent werd de "Disease Activity Score" (DAS), een zdekte-
activiteitsindex, bestaande uit kemset variabelen, ontwikkeld op basis van gegevens 
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van patiënten waarin de RA zich in een vroeg stadium bevond. In deze index zijn o.a. 
twee gewrichtsscores opgenomen. In Hoofdstuk 3 wordt een gemodificeerde index 
beschreven op grond van de gevonden resultaten van Hoofdstuk 1. Tevens werd 
onderzocht of de index een valide maat was voor patiënten met een langere ziekteduur. 
Geconcludeerd werd dat de validiteit en de mogelijkheid om te discrimineren tussen 
hoge en lage ziekte-activiteit van de gemodificeerde DAS (gewrichtsscores waarin 28 
gewrichten worden gemeten) vergelijkbaar is met de DAS waarin meer uitgebreide 
gewrichtsscores zijn opgenomen. Daarnaast werd geconcludeerd dat de ziekteduur de 
compositie van de DAS niet beïnvloedde. 
In Hoofdstuk 5 worden criteria besproken om de "response" van patiënten op 
behandeling te beoordelen. Deze criteria zijn gebaseerd op de DAS. De "response" op 
behandeling is afhankelijk van zowel een verandering in de tijd als van de uiteindelijk 
bereikte situatie. De criteria zijn dan ook dusdanig gedefinieerd dat daarin zowel de 
verandering van de DAS in de tijd als ook de eindwaarde van de DAS opgenomen 
zijn. Deze "response" criteria worden bovendien gevalideerd in dit hoofdstuk. Een 
daling van de DAS van meer dan 1.2 over de tijd, gecombineerd met een eindwaarde 
van een DAS van 2.4, bleek een goede "response" te zijn. 
In Hoofdstuk 6 wordt remissie geëvalueerd aan de hand van remissie-criteria 
die opgesteld zijn door het "American College of Rheumatology" (ACR). Beschreven 
wordt hoe vaak remissie voorkomt in de eerder genoemde onderzoekspopulatie, waarin 
patiënten zijn opgenomen vanaf het moment van diagnose. Dit heeft als voordeel dat 
er in deze groep weinig selectie naar de ernst van de ziekte heeft plaatsgevonden. Daar 
deze criteria echter variabelen bevatten die niet zijn opgenomen in de kemset, is de 
bruikbaarheid ervan in de toekomst beperkt. In dit hoofdstuk is geprobeerd om de 
relatie van deze criteria met de DAS te onderzoeken. Geconcludeerd wordt dat het 
aantal patiënten en het aantal momenten per jaar in remissie constant zijn over de 
ziekteduur. De criteria kunnen vervangen worden door de DAS, waardoor in plaats van 
een dichotome uitkomst, remissie ja/nee, remissie op het totale spectrum van ziekte-
activiteit geplaatst kan worden. 
De mortaliteit van patiënten met RA, een uitkomstmaat, wordt geëvalueerd in 
Hoofdstuk 7. Ook dit onderzoek vond plaats in de eerder beschreven patiëntenpo-
pulatie. Deze mortaliteit wordt vergeleken met de mortaliteit van een vergelijkbare 
onderzoeksgroep, waarin de RA zich ontwikkelde in de jaren 1957-1963. Gecon-
cludeerd wordt dat de mortaliteit gedurende de eerste zes jaar van de ziekte niet 
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afwijkt van die van de algemene Nederlandse populatie. Daarnaast was de mortaliteit 
van de populatie van 1985 niet verschillend van die van de populatie van 1957. De 
leeftijd blijkt de enige significante prognostische variabele te zijn. 
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STELLINGEN 
behorende bij het proefschrift 
CLINICAL ASSESSMENTS IN RHEUMATOID ARTHRITIS 
ASPECTS OF VALIDITY AND REPRODUCIBDLITY 
I 
Geen onderzoek wantrouwen is onnozel, alle onderzoeken wantrouwen dwaasheid, je eigen onderzoek 
wantrouwen de eerste stap naar de wijsheid. 
II 
Voor een gelovige statisticus is het bloedigste ogenblik der wereldgeschiedenis de eerste broedermoord: toen 
stierf 50% van de mannelijke jeugd. (Ernst Hohenemser) 
III 
De gewrichtsscores waarin 28 gewrichten zijn opgenomen zijn vergelijkbaar valide met scores waarin meer 
gewrichten zijn opgenomen, (<&t proefschrift) 
IV 
Gewrichtsscores berekend uit gewrichtsklachten (pijn en zwelling) die aangegeven worden door reumatoïde 
artritis patiënten in een vragenlijst verschillen van de scores berekend uit gegevens van gewrichtsonderzoek 
door de reumatoloog/verpleegkundige, (dit proefschrift) 
V 
Bij klinisch interventie-onderzoek is niet alleen de verandering in de tijd van belang maar ook de bereikte 
eindwaarde van de effectmaat. (dit proefschrift) 
VI 
De mortaliteit van patiënten waarin de reumatoïde artritis zich in een vroeg stadium bevindt, is niet hoger 
dan die van de Nederlandse bevolking, (dit proefschrift) 
VII 
Gezond leven houdt meer in dan Gezondheidswetenschapper te zijn. 
VIII 
Bij onderzoek met patiënten die reumatoïde artritis hebben moet rekening gehouden worden met de fase (de 
ziekteduur) waarin de ziekte zich bevindt. 
IX 
Dromen over de toekomst maakt dat men niet geniet van vandaag. 
X 
Promoveren is afzien in rok. 
Aiarlou Prevoo Zoetermeer, april 1995 



